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SUMMARY 
This report examines patterns and trends of colorectal cancer incidence, mortality, treatment and survival in Ireland during the 
period 1994-2010. 
Incidence 
11% (in women) and 14% (in men) of all invasive cancers (excluding non-melanoma skin cancer) were colorectal cancers in 
2007-2009, which makes this the second most common tumour diagnosed in women (after breast cancer), and in men (after 
prostate cancer)(Table 1). Colorectal cancer was the third leading cause of cancer death in women, after lung cancer and breast 
cancer, and the second leading cause of cancer death in men after lung cancer in 2007-2009. It accounted for 10% and 12% of 
cancer deaths in males and females respectively in 2007. Approximately 950 women and 1,330 men were diagnosed with 
colorectal cancer annually during 2007-2009. The incidence rate of colorectal cancer in Ireland was similar to the European 
average in 2008 (Figure 12). The numbers of colorectal cancer cases are projected to increase by 34% in women and 45% in 
men between 2010 and 2020.42 
 
 
Figure 1 
Age distribution of incident colorectal cancer (C18-20) 
Diagnosis period: 2006-2010 
FEMALES MALES 
  
  
Figure 2 
Site of primary colorectal tumour‡ 
Diagnosis period: 2006-2010 
FEMALES MALES 
 
‡colon (C18), rectosigmoid junction (RSJ, C19), rectum (C20) 
 
67% of women and 69% of men diagnosed with colorectal cancer were aged greater than 65 years (Figure 1). 14% of women 
and 11% of men presented aged less than 55 years. 22% of colorectal tumours in women occurred in the rectum compared 
with 30% for men (Figure 2). The ratio of male to female colorectal cancer is approximately 13:10. The ratio of colon to rectal 
cases is approximately 18:10 (15:10 in males and 23:10 in females). 
While the age standardised incidence rate for colorectal cancer in both sexes was static from 1994 to 2010, the actual number 
of cases increased at 1.8% annually for women and 2.3% for men over the same period. This was due to an increase in the Irish 
population during that period (Table 1).   
Mortality 
424 women and 550 men died from colorectal cancer in Ireland in 2008. For all colorectal cancer cases (C18-20), this report 
presents evidence of a steady annual decline in mortality rate, of 2.1% in women and 1.6% in men from 1994 to 2009. 
However, there was 2.8% annual increase in mortality rate in women and 2.4% increase in men for the subset of rectal cancer 
cases (C19-20) during the same period (Table 3). The ECO estimates of cancer deaths in 2008 showed that Ireland’s mortality 
rate was very close to the European average (Figure 23).  
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Survival 
Survival with colorectal cancer in Ireland was in line with the European average for the period 2000-2002 (Figure 18). This 
report highlights a trend towards significantly improved survival across the three diagnostic periods examined: 1994-1998, 
1999-2003 and 2004-2008.  
Treatment 
Surgery is the first line treatment for colorectal cancer. The proportion who received surgery did not change between 1995-
1999 (76%) and 2005-2009 (78%) (Table 16). The proportion of cases who received chemotherapy increased significantly, from 
27% during 1995-1999 to 43% for the period 2005-2009 (Table 17). The proportion of patients with rectal cancer who received 
radiotherapy increased from 24% in the period 1995-1999 to 40% in the period 2005-2009 (Table 18). Moreover, the 
proportion of cases with stage II/III rectal cancer (C19-20) who received pre-operative radiotherapy increased significantly from 
5% during 1995-1999 to 38% during 2005-2009 (Table 33).  
Table 1 
Summary data for colorectal cancer in Ireland (C18-20) 
 Females Males All trend 
% of all new cancer cases, 2007-2009 6.0% 9.2% 7.5% - 
% of all new cancer cases (excl. NMSC), 2007-2009  11.1% 14.2% 12.7% - 
Average number of new cases per year, 2007-2009 949 1,329 2,278 - 
^APC [±95%CI ] in number of cases, 1994-2010 1.8%[1.4, 2.1] 2.3%[2.0,2.7] 2.1%[1.8,2.4] ↑ 
Number of deaths during 2008   424   550   974 - 
^APC [±95%CI ] in number of deaths, 1994-2010 -0.3%[-0.9,0.4] 0.5%[-0.1,1.1] 0.2%[-0.3,0.6] ↔ 
Age-standardised incidence rate (per 100,000), 2007-2009 40.1 66.7 52.4 - 
^APC [±95%CI] in age standardised incidence rate, 1994-2010 0.0%[-0.4,0.4] 0.2%[-0.1,0.4] 0.1%[-0.1,0.4] ↔ 
Age-standardised mortality rate (per 100,000), 2008 16.4 27.7 21.5 - 
^APC [±95%CI ]in mortality rate, 1994-2009 -2.1% [-2.8,-1.4] -1.6% [-2.2,-1.0] -1.8% [-2.2,-1.4] ↓ 
‡15 year prevalence, 1995-2009 5,578 7,100 12,678 - 
‡10 year prevalence, 2000-2009 4,527 5,948 10,475 - 
 ‡5 year prevalence, 2005-2009 2,908 4,053 6,961 - 
^APC: annual percentage change 
‡The number of persons still alive on 31/12/2009, who were diagnosed during the period shown.  
 
 During the period 1994-2010, the number of colorectal cancer cases (C18-20) who presented in Ireland increased by 
2.1% annually. The APC in the number of deaths was static (+0.2% annually) during the same period (Table 1).  
 
 During the period 1994-2010, the number of colon cancer cases (C18) who presented in Ireland increased by 2.2% 
annually.  The number of deaths fell by 1.9% annually during the same period (Table 2).  
 
 During the period 1994-2010, the number of rectal cancer cases (C19-20) who presented in Ireland increased by 1.8% 
annually.  The number of deaths increased by 4.5% annually during the same period (Table 3).  
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Table 2 
Summary data for colon cancer in Ireland (C18) 
 Females Males All trend
% of all new cancer cases, 2007-2009 4.3% 5.7% 5.0% - 
% of all new cancer cases (excl. NMSC), 2007-2009  8.0% 8.8% 8.4% - 
Average number of new cases per year, 2007-2009    683    815     1,498 - 
APC [±95%CI ] in number of cases, 1994-2010 1.8%[1.4,2.3] 2.6%[2.0,3.2] 2.2%[1.8,2.7] ↑ 
Number of deaths during 2008 271 310 581 - 
APC [±95%CI ] in number of deaths , 1994-2010 -2.1%[-3.0,-1.2] -1.7%[-2.4,-1.0] -1.9%[-2.4,-1.3] ↓ 
Age-standardised incidence rate (per 100,000), 2007-2009 28.1 40.8 33.8 - 
APC [±95%CI] in age standardised incidence rate, 1994-2010 0.0%[-0.4,0.5] 0.5%[-0.1,1.0] 0.3%[-0.2,0.7] ↔ 
Age-standardised mortality rate (per 100,000), 2008 10.3 15.7 12.7 - 
APC [±95%CI ]in mortality rate, 1994-2009 -4.2% [-5.1,-3.2] -3.7% [-4.4,-3.0] -3.9%[-4.5,-3.3] ↓ 
15 year prevalence, 1995-2009 3,830 4,235 8,065 - 
10 year prevalence, 2000-2009 3,107 3,532 6,639 - 
  5 year prevalence, 2005-2009 2,021 2,449 4,470 - 
 
 
 
Table 3 
Summary data for cancer of the rectosigmoid junction and rectum in Ireland (C19-20) 
 Females Males All trend 
% of all new cancer cases, 2007-2009 1.7% 3.5% 2.5% - 
% of all new cancer cases (excl. NMSC), 2007-2009  3.1% 5.4% 4.3% - 
Average number of new cases per year, 2007-2009    267    514    781 - 
APC [±95%CI ] in number of cases, 1994-2010 1.7%[1.0,2.4] 1.9%[1.4,2.5] 1.8%[1.4,2.3] ↑ 
Number of deaths during 2008 153 240 393 - 
APC [±95%CI ] in number of deaths, 1994-2010 4.4%[3.0,5.9] 4.6%[3.4,5.9] 4.5%[3.5,5.6] ↑ 
Age-standardised incidence rate (per 100,000), 2007-2009 11.5 25.8 18.2 - 
APC [±95%CI] in age standardised incidence rate, 1994-2010 -0.1%[-0.9,0.7] -0.3%[-0.9,0.3] -0.1%[-0.6,0.4] ↔ 
Age-standardised mortality rate (per 100,000), 2008 6.2 12.1 8.8 - 
APC [±95%CI ]in age standardised mortality rate, 1994-2009 2.8%[1.2,4.4] 2.4%[1.1,3.6] 2.5%[1.5,3.5] ↑ 
15 year prevalence, 1995-2009 1,748 2,865 4,613 - 
10 year prevalence, 2000-2009 1,420 2,416 3,836 - 
 5 year prevalence, 2005-2009 887 1,604 2,491 - 
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1.  RISK FACTORS FOR COLORECTAL CANCER  
Up to 10% of colorectal cancers are hereditary and most of these are due to the genetic syndromes of familial adenomatous 
polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC).43 Excluding these syndromes, individuals who have a 
first degree relative with colorectal cancer have around a two-fold increased risk of developing the disease themselves. 
Lifestyle factors are extremely important in colorectal cancer. Smoking is causally related to colon, but not rectal, cancer. 
Alcohol is a cause of both colon and rectal cancers. Higher levels of body fatness, and in particular central adiposity, are 
positively related to risk. In a recent meta-analysis, each 5kg/m2 increment in body mass index was associated with an 18% 
increase in risk; the association appears stronger for colon than rectal cancer, for men than women, and in studies adjusting for 
physical activity.44 In contrast, physical activity is consistently inversely associated with colon cancer, in particular, and risk 
decreases in a dose-response fashion with increased frequency or intensity of activity. Regular use of aspirin or other non-
steroidal anti-inflammatory drugs may reduce colorectal cancer risk by up to half. In addition, risk is decreased in women taking 
hormone replacement therapy and is likely also to be lower in those who have taken oral contraceptives. Many studies have 
found increased risk in individuals who have higher intakes of processed meats (preserved by smoking, curing or salting, such as 
ham, bacon or salami) and red meats. In contrast, higher intake of various other dietary components may be associated with 
lower risk, including garlic; fruit; fish; non-starchy vegetables; milk, dairy products or calcium; coffee; soya and soya foods; and 
foods containing dietary fibre or the B vitamin folate. 
Table 4 
Risk factors for female colorectal cancer, by strength of evidence 
Evidence Increases risk Decreases risk 
Convincing or 
probable 
Family history of colorectal cancer  (first degree 
relative(s) with colorectal cancer)1 
Physical activity 3,4,11 
 Tobacco smoking (colon cancer only) 2 Hormone replacement therapy 12 
 Alcohol2 Oral contraceptives 12,13 
 Greater body fatness, in particular, abdominal 
fatness 3,4 
Aspirin and other non-steroidal anti-
inflammatory drugs 14 
 Red and processed meat 4 Foods containing dietary fibre 4 
 Asbestos 5 Garlic 4 
 Ionizing radiation (colon cancer only) 6 Non starchy vegetables 4,15 
Possible Disinfection by-products in drinking water 7 Fruit 4,15 
 Helicobacter pylori infection 8 Folate 16 
 Insulin-like growth factor-1 (IGF-1) 9 Fish 4 
 Diabetes 10 Coffee 17 
  Vitamin B6 intake and blood levels 18 
  Soya (women only)19 
  Milk, dairy and/or calcium 20 
  Vitamin D blood level21 
1 Johns and Houlston, 2001; 2 Secretan et al., 2009; 3 International Agency for Research on Cancer, 2002;  
4 World Cancer Research Fund / American Institute for Cancer Research, 2007;  5 Straif et al., 2009;  6 El Ghissassi et al., 2009;   
7 Rahman et al., 2010;  8 Zhao et al., 2008;  9 Rinaldi et al., 2010;  10 Larsson et al., 2005;  11 Harriss et al., 2009;  
12 International Agency for Research on Cancer, 2011a;  13 Bosetti et al., 2009;  14 International Agency for Research on Cancer, 
1997;  15 International Agency for Research on Cancer, 2003;  16 Kennedy et al., 2011;  17 Galeone et al., 2010;   
18 Larsson et al., 2010;  19 Yan et al., 2010;  20 Huncharek et al., 2009;  21 Yin et al., 2009 
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2.  INCIDENCE OF COLORECTAL CANCER 
2.1 Incidence of colorectal cancer: summary data 
Looking at both colon and rectal cancer together, the number of male cases increased from 983 in 1994 to 1,343 in 2010. 
Female cases increased from 769 in 1994 to 955 in 2010 (Figure 3).  
While the number of cases increased 
significantly in females (1.8% per annum) and 
males (2.3% per annum) due to an increase in 
the Irish population between 1994 and 2010, 
there was no actual change in the age 
standardised rate of colorectal cancer in 
Ireland between 1994 and 2010 (Table 5). 
 
 
 
 
 
 
 
Figure 3 
Age standardised incidence rate (ASR) and incident cases of invasive colorectal cancer (C18-C20): 1994-2010 
 
Table 5 
Incidence of invasive colorectal cancer (C18- C20): 1994-2010 
 Females Males All 
YEAR cases ASIR cases ASIR cases ASIR 
1994 769 40.9       983  65.3    1,752 51.8 
1995 756 40.7       935  61.7    1,691 49.9 
1996 715 36.7       986  64.7    1,701 49.6 
1997 798 41.2    1,022  64.9    1,820 51.9 
1998 779 39.8    1,024  64.3    1,803 50.8 
1999 789 38.8    1,026  63.6    1,815 50.1 
2000 802 39.3    1,037  63.0    1,839 50.1 
2001 809 39.4    1,107  66.1    1,916 51.2 
2002 806 37.7    1,068  62.4    1,874 48.8 
2003 837 38.9    1,103  62.8    1,940 49.7 
2004 924 42.1    1,161  64.1    2,085 52.2 
2005 866 38.6    1,211  65.3    2,077 50.9 
2006 928 40.3    1,199  63.1    2,127 50.6 
2007 944 41.6    1,317  68.1    2,261 53.8 
2008 929 39.0    1,293  65.0    2,222 50.9 
2009 975 39.8    1,376  67.1    2,351 52.5 
2010 955 38.7    1,343  63.7    2,298 50.3 
TOTAL   14,381    19,191    33,572  
APC 1.8% 0.0% 2.3% 0.2% 2.1% 0.1% 
[95%CI] [1.4, 2.1] [-0.4,0.4] [2.0,2.7] [-0.1,0.4] [1.8,2.4] [-0.1,0.4] 
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The number of male colon cancer cases increased from 605 in 1994 to 844 in 2010. Female colon cancer cases increased from 
554 in 1994 to 674 in 2010 (Figure 4).  
On average 683 females and 815 males were 
diagnosed with colon cancer (C18) in Ireland 
between 2007 and 2009. There was no change 
in the age standardised incidence rate of colon 
cancer (C18) in males and females between 
1994 and 2010. However, the actual number 
of cases increased significantly by 1.8% in 
females and 2.6% in males between 1994 and 
2010 due to an increase in the Irish population 
during this period (Table 6). 
 
 
 
 
 
 
Figure 4 
Age standardised incidence rate (ASR) and incident cases of invasive colon cancer (C18): 1994-2010 
 
Table 6 
Incidence of invasive cancer of the colon (C18): 1994-2010 
 Females Males All 
YEAR cases ASIR cases ASIR cases ASIR 
1994 554 29.6 605 40.0 1,159 34.2 
1995 545 28.9 565 37.1 1,110 32.4 
1996 508 25.7 591 38.5 1,099 31.5 
1997 554 28.5 589 37.2 1,143 32.3 
1998 519 26.2 586 36.7 1,105 30.9 
1999 545 26.5 625 38.6 1,170 32.0 
2000 560 27.1 614 37.3 1,174 31.6 
2001 569 27.6 619 37.0 1,188 31.6 
2002 573 26.7 603 35.0 1,176 30.3 
2003 575 26.0 616 35.0 1,191 30.0 
2004 630 28.1 719 39.7 1,349 33.4 
2005 600 27.0 743 40.0 1,343 32.7 
2006 637 27.3 728 38.3 1,365 32.2 
2007 661 29.1 804 41.5 1,465 34.7 
2008 679 28.1 779 39.2 1,458 33.1 
2009 708 28.8 862 42.1 1,570 34.9 
2010 674 27.0 844 39.9 1,518 32.9 
TOTAL 10,091  11,492  21,583  
APC 1.8% 0.0% 2.6% 0.5% 2.2% 0.3% 
[95%CI] [1.4,2.3] [-0.4,0.5] [2.0,3.2] [-0.1,1.0] [1.8,2.7] [-0.2,0.7] 
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Figure 5 
Age standardised incidence rate (ASR) and incident cases of invasive rectal cancer (C19-20): 1994-2010 
 
 
The number of male rectal cancer cases increased from 378 in 1994 to 499 in 2010. Female rectal cancer cases increased from 
215 in 1994 to 281 in 2010 (Figure 5).  
On average 267 females and 514 males were 
diagnosed with cancer of the rectosigmoid/rectum 
(C19-20) in Ireland between 2007 and 2009. There 
was no change in the age standardised incidence 
rate of cancer of the rectosigmoid/rectum (C19-
20). However, the actual number of cases 
increased significantly by 1.7% in females and 
1.9% in males between 1994 and 2010 due to an 
increase in the Irish population during this period 
(Table 7). 
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Table 7 
Incidence of invasive cancer of the rectum (C19-20): 1994-2010 
 Females Males All 
YEAR cases ASIR cases ASIR cases ASIR
1994 215 11.4 378 25.3 593 17.6
1995 211 11.8 370 24.6 581 17.5
1996 207 11.0 395 26.2 602 18.0
1997 244 12.7 433 27.7 677 19.6
1998 260 13.6 438 27.7 698 19.9
1999 244 12.3 401 25.0 645 18.1
2000 242 12.1 423 25.7 665 18.4
2001 240 11.8 488 29.1 728 19.6
2002 233 11.0 465 27.4 698 18.5
2003 262 12.8 487 27.8 749 19.6
2004 294 14.1 442 24.4 736 18.8
2005 266 11.6 468 25.4 734 18.1
2006 291 13.0 471 24.8 762 18.4
2007 283 12.5 513 26.6 796 19.2
2008 250 10.9 514 25.8 764 17.8
2009 267 11.0 514 25.0 781 17.6
2010 281 11.7 499 23.8 780 17.4
TOTAL 4,290  7,699 11,989
APC 1.7% -0.1% 1.9% -0.3% 1.8% -0.1%
[95%CI] [1.0,2.4] [-0.9,0.7] [1.4,2.5] [-0.9,0.3] [1.4,2.3] [-0.6,0.4]
 Colorectal cancer in Ireland: 1994-2010 Page  8 
 
2.2 Incidence of colorectal cancer by site of primary tumour 
 
Figure 6 
Anatomical site of colorectal cancers, 2005-2009: number and percentage of cases 
 
The sigmoid colon was the most common site of colon cancers for both sexes between 2005 and 2009 (Figure 6).  The 
distribution of cancers within the colon and rectosigmoid junction was similar for men and women, but rectal cancers were 
relatively more common in men. During the period 2005-2009, cancers of the rectum and rectosigmoid junction (combined) 
made up 38% of male colorectal cancers compared to 29% for females.  
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2.3 Incidence of colorectal cancer by age 
 
Table 8 
Age distribution of patients diagnosed with  colorectal cancer, by site of primary tumour and gender: 
 Diagnostic period 1995-1999, 2000-2004, 2005-2009 
SITE AGE 1995-1999 2000-2004 2005-2009 Total 
  No. % No. % No. % No. % 
  FEMALES 
CO
LO
N
 (C
18
) 
15-44 106 4% 99 3% 120 4% 325 4% 
45-54 222 8% 271 9% 272 8% 765 9% 
55-64 436 16% 489 17% 636 19% 1,561 18% 
65-74 764 29% 747 26% 881 27% 2,392 27% 
75+ 1,143 43% 1,301 45% 1,376 42% 3,820 43% 
Total 2,671 100% 2,907 100% 3,285 100% 8,863 100% 
 MALES
15-44 101 3% 87 3% 120 3% 308 3% 
45-54 243 8% 251 8% 304 8% 798 8% 
55-64 603 20% 591 19% 794 20% 1,988 20% 
65-74 1,022 35% 1,120 35% 1,275 33% 3,417 34% 
75+ 987 33% 1,122 35% 1,423 36% 3,532 35% 
Total 2,956 100% 3,171 100% 3,916 100% 10,043 100% 
RE
CT
U
M
 (C
19
-2
0)
 
 FEMALES 
15-44 57 5% 75 6% 75 6% 207 5% 
45-54 111 10% 156 12% 164 12% 431 11% 
55-64 228 20% 232 18% 260 19% 720 19% 
65-74 343 29% 366 29% 314 23% 1,023 27% 
75+ 427 37% 442 35% 544 40% 1,413 37% 
Total 1,166 100% 1,271 100% 1,357 100% 3,794 100% 
 MALES
15-44 55 3% 62 3% 76 3% 193 3% 
45-54 221 11% 252 11% 275 11% 748 11% 
55-64 460 23% 553 24% 620 25% 1,633 24% 
65-74 717 35% 764 33% 787 32% 2,268 33% 
75+ 584 29% 674 29% 722 29% 1,980 29% 
Total 2,037 100% 2,305 100% 2,480 100% 6,822 100% 
 
For colon cancer incident during 1995-2009, 43% of female cases and 35% of male cases were older than 75 years.  For rectal 
cancer incident during 1995-2009, 37% of female cases and 29% of males cases were older than 75 years (Table 8). For females, 
there was no change in the age distribution of colon or rectal cases across three diagnostic periods 1995-1999, 2000-2004 and 
2005-2009.  For male colon cancer cases, there was a significant upward shift in the proportion diagnosed in the 75+ age group 
from 33% during 1995-1999 to 36% during 2005-2009 (Table 8, Figure 9). For male rectal cases, there was no change in the 
proportion diagnosed in each of the age categories, across the three diagnostic periods.  
 
The ratio of male to female colorectal cancer cases was stable at 13:10 across the three diagnostic periods. The ratio of colon to 
rectal cases did not vary from 18:10 over the same periods (15:10 in males and 23:10 in females). 
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Figure 7 
Age-specific incidence of invasive cancer of the colon (C18): diagnostic periods 1995-1999 & 2005-2009 
 (a) Number of cases by age group & age-specific incidence (b) percentage (of the total) cases by age group 
FE
M
A
LE
S 
M
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The numbers of cases presenting, and age-specific incidence rates in each 5-year age group are presented for colon cancer in 
Figure 7(a).   
For females, the median age of diagnosis was 72 years for both 1995-1999 and 2005-2009. For males, the median age rose 
from 70 years in 1995-1999 to 71 years during 2005-2009. The number of cases presenting was highest in the 75-79 age group 
for females and 70-74 age group for males. For females, there were no significant differences in age-specific incidence rates for 
each age group between 1995-1999 and 2005-2009.  However, for male cases, in the latter diagnostic period, there was a 
significant increase in the age-specific rates for the age groups 75-79 and 85+ (Figure 7a & Figure 9).  
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Figure 8 
Age-specific incidence of invasive cancer of the rectum (C19-20): diagnostic periods 1995-1999 & 2005-2009 
 (a) Number of cases by age group & age-specific incidence (b) percentage (of the total) cases by age group 
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The numbers of cases presenting, and age-specific incidence rates in each 5-year age group are presented for rectal cancer in 
Figure 8(a).   
For females, the median age at diagnosis increased from 70 years for the period 1995-1999 to 71 years for the period 2005-
2009. For males, the median age was 68 years for both periods. The number of cases presenting was highest in the 75-79 age 
group for females and in the 65-69 and 70-74 age groups for males. For both sexes, there were no significant differences in age-
specific incidence rates for each age group between 1995-1999 and 2005-2009 (Figure 8a & Figure 9).  
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There was a significant annual 1.6% increase in the age-specific incidence rate (ASIR) of colon cancer (C18) in the oldest age 
group (75+ years) in males. Otherwise, there was no change in the ASIR for any age category in colon or rectal cancer (Figure 9). 
 
 
 
 
 
 
 
 
 
Figure 9 
Annual percentage change (APC) in age-specific incidence rate (ASIR) for invasive colorectal cancer (C18-C20): 1994-2010 
  
FEMALES MALES 
CO
LO
N
 (C
18
) 
Age cases% APC 95%CI trend 
15-44 yr 4% 1.3% [-1.2,  3.7%] ↔ 
45-54 yr 9% -0.2% [-1.7,  1.2%] ↔ 
55-64 yr 17% -0.5% [-2.0,  1.1%] ↔ 
65-74 yr 27% 0.1% [-0.9, 1.1%] ↔ 
75+ yr 43% 0.5% [-0.1, 1.1%] ↔ 
 
Age cases% APC 95%CI trend 
15-44 yr 3% 1.0% [-1.6,  3.8%] ↔ 
45-54 yr 8% -0.8% [-2.4, 0.9%] ↔ 
55-64 yr 20% -0.7% [-1.9, 0.4%] ↔ 
65-74 yr 34% 0.5% [-0.2,  1.2%] ↔ 
75+ yr 35% 1.6% [1.1,  2.1%] ↑ 
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Age cases% APC 95%CI trend 
15-44 yr 5% 4.1% [-0.3,  8.6%] ↔ 
45-54 yr 11% 1.9% [-0.2,  4.0%] ↔ 
55-64 yr 19% -1.7% [-3.7,  0.4%] ↔ 
65-74 yr 27% -0.7% [-2.0,  0.8%] ↔ 
75+ yr 37% 0.2% [-1.2,  1.6%] ↔ 
 
Age cases% APC 95%CI trend 
15-44 yr 3% 2.1% [-0.4,  4.5%] ↔ 
45-54 yr 11% 0.3% [-1.2, 1.8%] ↔ 
55-64 yr 24% -0.4% [-1.2, 0.3%] ↔ 
65-74 yr 33% -0.7% [-1.6,  0.2%] ↔ 
75+ yr 29% 0.3% [-0.7,  1.3%] ↔ 
 Points on graphs indicate actual age-specific incidence rate. Lines indicate fitted trends (Joinpoint)30 
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2.4 Geographical variation in incidence  
Variation in colorectal cancer incidence at county level in 2006-2010 is presented in Figure 10. Age standardised rates (ASR)   
for incidence were calculated for the period 2006-2010 for each county. The incidence rate for Ireland as a whole was 39.9 
(95%CI: 38.7, 41.0) per 100,000 females and 65.4 (95%CI: 63.8, 67.0) per 100,000 males.a Standardised rate ratios (SRR) were 
calculated as the ratio between the ASR in each country and the national ASR. For females, the incidence rate was significantly 
higher in Cork county than the national average and significantly lower than the national average in Kildare. For males, the 
incidence was significantly higher than the national average in Cork county and significantly lower than the national average in 
Kilkenny and Meath.  
Counties are demarcated by largely arbitrary boundaries, with great variation in population densities. Geographical variation in 
incidence rates may be better visualised by consulting the all-Ireland cancer atlas which describes incidence ratios at the level 
of approximately 3,500 electoral divisions in RoI, and 580 wards in Northern Ireland during 1995-2007.22 
The distribution of cases between HSE areas 
remained quite constant between 1995-1999 
and 2005-2009, with just under a half living in 
the two eastern regions (Table 9). 
 
 
                                         
a Appendix II statistical methods  
Figure 10 
County-level variation in colorectal cancer incidence 
Standardised rate ratios (SRR) relative to incidence rate  for Ireland: 2006-2010 
FEMALES MALES
  
 
Table 9 
Area of residence and number of  colorectal cancer patients 
Diagnostic periods 1996-2000, 2001-2005, 2006-2010 
HSE area of residence 1995-1999 2000-2004 2005-2009 
  cases % of 
 cases 
cases % of 
cases 
cases % of 
cases 
Dublin Mid Leinster 2,394 27% 2,644 27% 3,125 28% 
Dublin North East 1,726 20% 1,932 20% 2,105 19% 
South 2,438 28% 2,617 27% 3,049 28% 
West  2,272 26% 2,461 25% 2,759 25% 
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2.5 Method of verification, morphology and tumour grade 
 
Table 10 
Method of verification of  colorectal tumours (C18-20) 
Method of 1995-1999 2000-2004 2005-2009 
verification  cases % of  
cases
cases % of  
cases 
cases % of 
cases
Histological 7,853 89% 8,814 91% 10,407 94%
Clinical only 667 8% 616 6% 491 4%
Unknown 310 4% 224 2% 140 1%
 
Table 11 
Morphology of colorectal cancer tumours 
Morphology 1995-1999 2000-2004 2005-2009 
 cases % of  
cases 
cases % of  
cases 
cases % of 
cases
Adenocarcinoma 6,832 77% 7,809 81% 9,313 84%
Mucinous type 751 9% 766 8% 807 7%
Other morphology 232 3% 209 2% 266 2%
Unspecified 1,015 11% 870 9% 652 6%
 
 
The number of cases assigned to each diagnostic verification method is shown in Table 10. The proportion of cases confirmed 
using histological methods increased from 89% to 94% in the periods 1995-1999 and 2005-2009 respectively.  
 
The number of cases assigned to each morphological classification is shown in Table 11. The majority of colorectal tumours 
showed adenocarcinoma morphology (84% in the period 2005-2009). The proportion of unspecified morphology tumours 
decreased from 11% to 6% in the periods 1995-1999 and 2005-2009 respectively, which is probably reflective of more precise 
pathology laboratory reporting over the last 10 years. 
 
 
The number of cases assigned by grade of tumour is 
presented in Table 12. 
The proportion of unspecified grade tumours decreased 
from 25% to 18% in the periods 1995-1999 and 2005-2009 
respectively which is probably reflective of more precise 
pathology laboratory reporting over the last 10 years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12 
Grade  of  colorectal tumours 
Level of  1995-1999 2000-2004 2005-2009 
differentiation  cases % of  
cases 
cases % of  
cases 
cases % of 
cases 
Good 899 10% 740 8% 545 5% 
Moderate 4,544 51% 5,533 57% 7,066 64% 
Poor 1,145 13% 1,066 11% 1,393 13% 
Unspecified 2,242 25% 2,315 24% 2,034 18% 
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2.6 Stage at diagnosis  
  
Table 13 
Stage of disease at diagnosis for colon cancer (C18) , by gender 
 Females Males 
 1995-1999 2000-2004 2005-2009 1995-1999 2000-2004 2005-2009 
 cases % cases % cases % cases % cases % cases % 
stage I, Duke’s A 318 12% 325 11% 367 11% 394 13% 369 12% 434 11% 
stage II, Duke’s B 843 32% 898 31% 943 29% 967 33% 916 29% 1,189 30% 
stage III, Duke’s C 576 22% 678 23% 900 27% 623 21% 782 25% 1,010 26% 
stage IV 536 20% 638 22% 730 22% 666 23% 807 25% 948 24% 
unstaged 398 15% 368 13% 345 11% 306 10% 297 9% 335 9% 
Total 2,671 100% 2,907 100% 3,285 100% 2,956 100% 3,171 100% 3,916 100% 
 
The proportion of cases with colon cancer presenting at stage I decreased from 12% to 11% for females and 13% to 11% for 
males between 1995-1999 and 2005-2009 (Table 13). Similarly, for stage II, the proportion of cases decreased from 32% to 
29%, and 33% to 30% for females and males respectively between 1995-1999 and 2005-2009. Conversely, the proportion of 
cases presenting at stage III increased substantially, from 22% to 27% and 21% to 26% for females and males respectively 
between 1995-1999 and 2005-2009. There were also smaller increases in the proportion of cases diagnosed at stage IV for both 
sexes (females; 20% to 22% and males; 23 to 24%) between 1995-1999 and 2005-2009 (Table 13). 
 
Table 14 
Stage of disease at diagnosis for cancer of the rectosigmoid junction (C19) and rectum (C20), by gender 
 Females Males 
 1995-1999 2000-2004 2005-2009 1995-1999 2000-2004 2005-2009 
 cases % cases % cases % cases % cases % cases % 
stage I, Duke’s A 255 22% 262 21% 220 16% 396 19% 401 17% 371 15% 
stage II, Duke’s B 287 25% 292 23% 298 22% 539 26% 538 23% 524 21% 
stage III, Duke’s C 246 21% 319 25% 406 30% 413 20% 626 27% 758 31% 
stage IV 210 18% 222 17% 239 18% 433 21% 491 21% 534 22% 
unstaged 168 14% 176 14% 194 14% 256 13% 249 11% 293 12% 
Total 1,166 100% 1,271 100% 1,357 100% 2,037 100% 2,305 100% 2,480 100% 
 
The proportion of cases with cancer of the rectosigmoid and rectum presenting at stage I decreased from 22% to 16% for 
females and 19% to 15% for males between 1995-1999 and 2005-2009 (Table 14). Similarly, for stage II, the proportion of cases 
decreased from 25% to 22% and 26% to 21% for females and males respectively between 1995-1999 and 2005-2009. 
Conversely, the proportion of cases presenting at stage III increased substantially, from 21% to 30% and 20% to 31% for 
females and males respectively between 1995-1999 and 2005-2009. There was little change over time in the proportions 
presenting at stage IV for both sexes (Table 14). 
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Figure 11 
Case fraction for stage of disease at presentation, by gender and site of tumour: diagnostic period 1994-2009 
 FEMALES MALES 
CO
LO
N
 (C
18
) 
 
Stage of disease From to APC 95%CI trend
Stage I & II 1995 2009 -1.2% [-1.9, -0.5%] ↓
Stage III & IV 1995 2009 1.1% [0.5,  1.6%] ↑
 
Stage of disease From to APC 95%CI trend
Stage I & II 1995 2009 -1.2% [-2.0, -0.4%] ↓
Stage III & IV 1995 2009 1.1% [0.4,  1.9%] ↑
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Stage of disease From to APC 95%CI trend
Stage I & II 1995 2009 -1.8% [-2.7, -0.8%] ↓
Stage III & IV 1995 2009 1.8% [0.8,  2.8%] ↑
 
Stage of disease From to APC 95%CI trend
Stage I & II 1995 2009 -2.2% [-2.9, -1.4%] ↓
Stage III &IV 1995 2009 1.9% [1.2,  2.6%] ↑
 
 
Case fractions presenting at stage I & II or stage III & IV, and the annual percentage change (APC) over the years 1994-2009 
were calculated and presented for tumour site and gender (Figure 11).  
 
For colon tumours (C18), there was a significant annual percentage decrease in the case fraction presenting at stage I & II 
between 1995 and 2009  (-1.2% for both males and females). Conversely, there was a significant annual increase in the case 
fraction presenting at stage III & IV over the same period (1.1% for both males and females). For rectal tumours (C19-20), there 
was a significant annual percentage decrease in the case fraction presenting  at stage I & II between 1995 and 2009 (-1.8% for 
females, -2.2% for males). Conversely, there was a significant annual percentage increase in the case fraction presenting at 
stage III & IV (1.8% for females, 1.9% for males). 
 
These data suggest that more comprehensive investigation in the peri-operative period resulted in a significant shift in stage 
allocation from stage I/II to stage III/IV over the years 1995-2009.   
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2.7 International comparison of incidence 
 
Estimated age standardised incidence rates 
(ASIR) for 2008 are presented in Figure 12.23  
 
Within Europe in 2008, the highest incidence of 
colorectal cancer in men was in Hungary, the 
Czech Republic and Slovakia. The highest 
incidence of colorectal cancer in women was in 
Denmark, Norway and the Netherlands. The 
lowest incidence, for both sexes, was in Cyprus 
and Greece.  
 
Ireland had a higher incidence of colorectal 
cancer (43 and 67/100,000 for women and men 
respectively) than its nearest neighbour, the 
United Kingdom (35 and 55/100,000 for women 
and men respectively), and also higher than the 
EU average (37 and 60/100,000 for women and 
men respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 
Estimated incidence of colorectal cancer, 2008  
European Cancer Observatory (ECO) 23
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3.  TREATMENT 
3.1 Treatment options for colorectal cancer 
 
Patients with resectable rectal cancer are recommended to undergo preoperative short-course radiotherapy (25Gy in 5 
fractions in 1 week), with surgery performed within 1 week of completion of radiation.45  However, in certain cases it may be 
decided that the benefits of treating patients with lower-risk disease does not justify the additional toxicity of radiotherapy. 
In some cases of rectal cancer, radiotherapy (with synchronous chemotherapy) may be appropriate to downstage the tumour. 
A dose of 45Gy in 25 fractions over 5 weeks, with or without a reduced volume boost dose of 5.4-9Gy in 3-5 fractions, is 
recommended.45   If the addition of radiotherapy to surgery is deemed necessary for rectal cancer, it should ideally be given 
pre-operatively.46 However, in cases with predictive factors for local recurrence (e.g. evidence of tumour at the circumferential 
resection margin, mesorectal lymph node involvement and extramural vascular invasion), post operative radiotherapy and 
chemotherapy should be considered for patients who did not receive pre-operative radiotherapy. A fluoropyrimidine as 
monotherapy or oxaliplatin in combination with 5-fluorouracil and folinic acid are commonly used chemotherapy options for 
the adjuvant treatment of patients with node-positive colorectal cancer following potentially curative surgery.45 
 
Table 15 
Summary of treatment options for colorectal cancer 45 
 Colon (C18) Rectum  (C19-20) 
Stage I 
T1-T2, NO, MO 
Resection T1: local excision, total mesorectal excision 
T2: total mesorectal excision 
T2: pre-operative radiotherapy 
Stage II 
T3-T4, NO, MO 
Resection 
Adjuvant chemotherapy should be considered 
for high risk patients‡  
Total mesorectal excision 
Preoperative radiotherapy, or 
Preoperative radiotherapy (and (neo-)adjuvant 
chemotherapy 
Stage III 
T (any), N1-2, MO 
Resection 
Adjuvant chemotherapy 
Total mesorectal excision 
Preoperative radiotherapy, or 
Preoperative radiotherapy (and (neo-)adjuvant 
chemotherapy 
Stage IV 
T(any), N(any), M1 
Consider resection (palliative/curative) 
Consider chemotherapy (palliative/curative) 
Consider resection (palliative/curative) 
Consider chemotherapy (palliative/curative) 
‡high risk: stage II, pT4, poorly differentiated tumour with angio-invasion, and low number of nodes sampled 
45 Guidelines for the Management of Colorectal Cancer, 3rd edition (2007). Issued by: The Association of Coloproctology of 
Great Britain and Ireland 
 
For the treatment of advanced disease, in fit patients with inoperable but non-metastatic rectal carcinoma, primary chemo-
radiation should be considered. When the course is completed, the tumour should be re-staged and potentially curative 
resection considered if appropriate. Fit patients with operable or potentially operable liver or lung metastases should be 
reviewed in the MDT with a hepatobiliary (or thoracic) surgeon and colorectal oncologist, to evaluate operability and to decide 
on a combined plan of management to optimise the chance of successful resection of all metastatic disease.  Patients with 
evidence of unresectable metastatic disease should be considered for palliative chemotherapy.45 
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3.2 Treatment receivedb 
 
Primary course of treatment was defined as receipt of any: surgery, chemotherapy or radiotherapy, up to one year after 
diagnosis date. In the following sections, ‘treatment’ refers to primary course of treatment only. 
 
Table 16 
Number and percentage of all patients in receipt of surgery‡: 1995-1999, 2000-2004, 2005-2009 
 1995-1999 2000-2004 2005-2009 Change in annual case 
fraction 
Site of primary tumour patients surgery% patients surgery% patients surgery% APC%[95%CI] *trend 
Colon (C18) 5,627 76% 6,078 76% 7,201 79% 0.3[0.0, 0.6] ↑ 
Rectum (C19, C20) 3,203 75% 3,576 73% 3,837 75% -0.1[-0.5, 0.3] ↔ 
Combined (C18-20) 8,830 76% 9,654 75% 11,038 78% 0.2[-0.1, 0.4] ↔ 
*Annual percentage change (APC) over 1995-2009:↑=significant increase, ↓=significant decrease, ↔=no change 
‡ Received tumour destructive surgery (ICD-9-CM codes 45.4x, 45.7x, 45.8, 48.3, 48.35, 48.36, 48.4, 48.49, 48.5, 
48.6x, 48.82)41, regardless of age and stage. 
 
Regardless of stage, over 75% of colorectal cancer cases underwent surgery during 2005-2009. The proportion of cases with 
colon cancer who received surgery increased marginally from 76% to 79% between 1995-1999 and 2005-2009. There was no 
change in the proportion of cases who received surgery for cancer of the rectum over the period 1995-2009 (Table 16).  
Table 17 
Number and percentage of all patients in receipt of chemotherapy‡: 1995-1999, 2000-2004, 2005-2009 
 1995-1999 2000-2004 2005-2009 Change in annual case fraction
Site of primary  patients chemotherapy% patients chemotherapy% patients chemotherapy% APC%[95%CI] *trend
Colon (C18) 5,627 26% 6,078 34% 7,201 38% 4.1[2.7, 5.4] ↑
Rectum (C19, C20) 3,203 28% 3,576 44% 3,837 51% 6.1[4.5, 7.7] ↑
Combined  8,830 27% 9,654 38% 11,038 43% 4.8[3.4, 6.3] ↑
*Annual percentage change (APC) over 1995-2009:↑=significant increase, ↓=significant decrease, ↔=no change 
 ‡regardless of age, stage at presentation and whether patient underwent surgery 
 
Regardless of stage and receipt of surgery, the proportion of cases with colon cancer who received chemotherapy increased 
from 26% to 38% between 1995-1999 and 2005-2009, while the proportion of cases with cancer of the rectum who received at 
least one chemotherapy administration increased significantly from 28% to 51% over the same period (Table 17).  
Table 18 
Number and percentage of all rectal cancer patients (C19-20) in receipt of radiotherapy‡: 1995-1999, 2000-2004, 2005-2009 
 1995-1999 2000-2004 2005-2009 Change in annual case 
fraction 
Site of primary  patients radiotherapy% patients radiotherapy% patients radiotherapy% APC%[95%CI] *trend
Rectum (C19, C20) 3,203 24% 3,576 37% 3,837 40% 5.3[3.5, 7.1] ↑
*Annual percentage change (APC) over 1995-2009:↑=significant increase, ↓=significant decrease, ↔=no change 
 ‡regardless of age, stage at presentation, receipt of surgery and sequence of receipt (pre-operative and/or post 
operative) 
 
Regardless of stage and receipt of surgery, the proportion of cases with rectal cancer who received radiotherapy increased 
from 24% to 40% between 1995-1999 and 2005-2009 (Table 18).  
 
 
                                         
b Appendix II: Treatment definitions 
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Most patients (70%) presenting with colon cancer in the 
period 1995-2009 were older than 65 years (Table 8 
above).  
More than 90% of colon cases presenting at stage I-III 
received surgery as their first line treatment. During the 
period 2005-2009, 99% of cases <45 years received 
surgery, decreasing slightly with increasing age to 92% for 
patients >75 years (Table 19).  
 
A small proportion of younger cases with stage I disease 
received adjuvant chemotherapy, falling from 12% in 
those <45 years to 3% in those aged 65-74 years.  
 
A larger proportion of stage II colon cases received 
adjuvant chemotherapy, falling steadily from 76% in cases 
aged <45 years, to 6% of cases aged > 75 years.  
 
89% of patients aged <45 years with stage III disease 
received adjuvant chemotherapy. This figure fell gradually 
to 76% for patients aged 65-74; only 29% of patients aged 
>75 years received chemotherapy.  
 
In the period 2005-2009, the proportion of stage IV 
patients who received a resection of the primary tumour 
fell from 64% in the youngest age group to 38% in those 
>75 years.  Over the same period, the proportion who received chemotherapy fell from 84% of patients aged <45 years to 27% 
of those >75 years. See Appendix III, Table 49, for a full tabulation of treatment combinations presented in order of the 
temporal sequence of receipt.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 19 
Primary treatment for colon cancer (C18) by stage and age;  
percentage of patients who underwent the respective treatment
  Period of diagnosis 
Treatment age 1995-1999 2000-2004 2005-2009
 years % % %
Resection 15-44 99 98 99
stage I-III 45-54 95 97 97
 55-64 96 97 97
 65-74 95 95 96
 75+ 93 93 92
Adjuvant chemotherapy 15-44 36 12 12
stage I 45-54 14 9 13
 55-64 13 9 5
 65-74 6 7 3
 75+ 3 3 0
Adjuvant chemotherapy 15-44 67 67 76
stage II 45-54 58 66 58
 55-64 45 53 43
 65-74 25 31 31
 75+ 6 6 6
Adjuvant chemotherapy 15-44 82 82 89
stage III 45-54 75 83 84
 55-64 68 82 89
 65-74 49 71 76
 75+ 15 26 29
Resection of primary 15-44 70 68 64
stage IV 45-54 62 59 64
 55-64 61 54 63
 65-74 53 54 54
 75+ 43 39 38
Chemotherapy 15-44 77 75 84
stage IV  45-54 61 73 78
(with or without surgery) 55-64 53 65 80
 65-74 29 51 60
 75+ 7 14 27
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Pre-operative radiotherapy has been recommended for resectable rectal cancer in recent years.45,46   The receipt of this 
treatment according to stage and age was explored in Table 20.  63% of patients presenting with rectal cancer in the period 
1995-2009 were older than 65 years (Table 8 above). 
The majority of patients aged <75 years presenting 
with stage I-III rectal cancer between 1995 and 2009 
received surgery (>90%) (Table 19). For cases >75 
years, the resection rate fell to less than 90% (Table 
20).  
 
The proportion who received pre-operative 
radiotherapy has increased markedly since 2000. 
Younger cases (<65) were more likely to receive the 
treatment relative to the older subset (>65 year). 
 
During the diagnostic period 2005-2009, 
approximately 1 in 5 patients presenting with stage I 
disease received pre-operative radiotherapy, falling to 
less than 1 in 10 for cases >75 years.  
 
Approximately half of younger cases (<65 years), 
presenting with stage II-III rectal cancer received pre-
operative radiotherapy. Patients > 65 years presenting 
with stage III disease were more likely to receive pre-
operative radiotherapy than stage II patients of the 
same age group (Table 20).  
 
Resection of the primary tumour was less common for 
cases presenting with stage IV disease. During the 
period 2005-2009, 67% of such patients <45 years 
received surgery, falling steadily with age to 28% of 
patients >75 years. Chemotherapy was very common 
in the stage IV subset, with 93% of patients under 45 years receiving it, either as an adjuvant treatment, or as monotherapy. 
Only a quarter of patients greater than 75 years received chemotherapy.  
 
See Appendix III, Table 49, for a full tabulation of treatment combinations presented in order of the temporal sequence of 
receipt.  
 
 
 
 
Table 20 
Trends in primary treatment for patients with rectal cancer (C19-20)
 According to age, stage and percentage of patients who underwent 
the respective treatment 
  period of diagnosis  
Treatment Age 
years 
1995-1999 2000-2004 2005-2009
  % % %
Resection 15-44 96 90 96
Stage I-III 45-54 95 95 93
 55-64 94 92 94
 65-74 91 91 93
 75+ 89 82 81
Pre-operative radiotherapy 15-44 0 4 23
Stage I ‡ 45-54 1 10 18
 55-64 2 11 13
 65-74 2 8 20
 75+ 1 7 9
Pre-operative radiotherapy 15-44 6 27 57
Stage II‡ 45-54 13 28 47
 55-64 9 22 42
 65-74 5 19 32
 75+ 2 7 16
Pre-operative radiotherapy 15-44 3 23 52
Stage III‡ 45-54 7 30 46
 55-64 3 24 41
 65-74 4 21 39
 75+ 0 9 20
Resection of primary 15-44 52 56 67
Stage IV 45-54 56 49 51
 55-64 63 53 41
 65-74 46 34 43
 75+ 28 29 28
Chemotherapy  15-44 70 94 93
Stage IV 45-54 61 84 88
(with or without surgery) 55-64 50 73 75
 65-74 26 56 72
 75+ 10 17 26
‡pre-op radiotherapy with or without adjuvant chemotherapy 
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3.3 Region of surgery 
 
Table 21 
HSE-area of colon surgery (C18) relative to HSE area of 
residence. Diagnostic periods: 2000-2004, 2005-2009 
HSE area of residence HSE area of surgery 
DNML DNNE South West
2000-2004  
DNML 91% 6% 1% 2%
DNNE 9% 90% 1% 1%
South 7% 1% 87% 4%
West  9% 3% 2% 85%
2005-2009  
DNML 90% 7% 1% 2%
DNNE 11% 89% - -
South 6% 1% 91% 2%
West 7% 3% 3% 88%
 
Table 22 
HSE-area of rectal surgery (C19-20) relative to HSE area 
of residence. Diagnostic periods: 2000-2004, 2005-2009
HSE area of residence HSE area of surgery 
DNML DNNE South West
2000-2004  
DNML 91% 7% 1% 1%
DNNE 25% 73% 1% 1%
South 11% 3% 81% 5%
West  25% 4% 2% 68%
2005-2009  
DNML 93% 5% 1% 1%
DNNE 29% 71% - -
South 12% 2% 82% 4%
West 12% 3% 2% 84%
The proportion of patients who underwent tumour resection, by HSE area of residence and HSE area of treatment, is presented 
in Table 21-22.  For cases presenting with colon tumours during the period 2005-2009 (Table 21), almost all cases resident in 
the two eastern HSE areas had their surgery within one of these areas. 9% of cases resident in HSE South and 13% of those 
resident in HSE West travelled to other HSE areas for their surgery.   
For rectal surgery, in the period 2005-2009, almost all patients resident within DNML or DNNE underwent their surgery in one 
of those areas. For patients presenting in HSE South, 82% of them had their surgery in that region, with 14% undergoing the 
index operation in the one of the eastern regions. Similarly, for patients originating in HSE west, 84% underwent their index 
surgery in HSE West, with 15% undergoing the procedure in one of the HSE eastern regions (Table 22).  
3.4 Surgeon caseload 
 
Table 23 
Case volume of surgeons: Diagnostic periods: 1995-1999, 2000-2004, 2005-2009 
Colon (C18) Rectum (C19-20) 
 1995-1999 2000-2004 2005-2009 
Surgeons, 
resections/yr^ 
resections 
‡ 
% resections 
‡ 
% resections
‡
%
low vol: <10 1,983 44% 1,765 35% 1,607 25%
mid vol :11-19 1,666 37% 2,114 42% 1,814 29%
high vol:>20 816 18% 1,129 23% 2,898 46%
Total 4,465 100% 5,008 100% 6,319 100%
 1995-1999 2000-2004 2005-2009 
surgeon 
resections/yr^
resections
‡
% resections 
‡ 
% resections
‡
%
low vol: <10 1,367 54% 1,183 42% 718 22%
mid vol: 10-15 451 18% 490 17% 847 26%
high vol: >15 732 29% 1,171 41% 1,651 51%
Total 2,550 100% 2,844 100% 3,216 100%
chi2 test,  p<0.0001 chi2 test,  p<0.0001 
‡Counts of surgical resections performed up to one year after diagnosis in patients with invasive colorectal cancer, by diagnostic 
period (Appendix II: treatment definitions). Figures include multiple resections performed on the same patient.   
^ Surgeons were categorised according to the average number of such colorectal resections performed annually; averaged over each 
of the five year diagnostic periods: 1995-1999, 2000-2004,2005-2009 
For colon cancer cases, 4,465 resections were performed during 1995-1999 as part of the primary course of treatment. Of 
these, 1,983 (44%) were performed by surgeons with an average annual rate of <10 per year for such resections (low volume), 
and 816 (18%) were performed by surgeons with an annual average rate of >20 per year for such resections (high volume) 
(Table 23). By 2005-2009, the situation had reversed significantly; the proportion of resections performed by ‘high volume’ 
surgeons had increased from 18% (1995-1999) to 46% in 2005-2009, with a decrease in the number of resections performed by 
‘low volume’ surgeons (44% to 25%) and ‘mid volume’ surgeons (37% to 29%).  
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A similar shift in operating patterns was observed for resections of the rectum.  2,550 resections were performed during 1995-
1999 as part of the primary course of treatment. Of these, 1,367 (54%) were performed by surgeons with an average annual 
rate of <10 per year for such resections (low volume), and 732 (29%) were performed by surgeons with an annual average rate 
of >15 per year for such resections (high volume) (Table 23). By 2005-2009, the situation had reversed significantly; the 
proportion of resections performed by ‘high volume’ surgeons had increased from 29% (1995-1999) to 51% in 2005-2009, with 
a decrease in the number of resections performed by ‘low volume’ surgeons (54% to 22%). In summary, moving from the 
earlier diagnostic period (1995-1999) to the latest diagnostic period (2005-2009), a greater proportion of colorectal cancer 
resections were performed by ‘high volume’ surgeons (Table 23). 
3.5 Hospital caseload: surgery 
 
Table 24 
Surgical caseload by hospital: Diagnostic periods 1995-1999, 2000-2004, 2005-2009 
Tumours originating in the colon (C18)  
 1995-1999 2000-2004 2005-2009 
 resections ‡ % resections ‡ % resections ‡ % 
Total                  4,465  100%                5,008  100%                6,319  100% 
St. James’s Hospital, DN                      266  6%                    274  5%                    411  7% 
Beaumont Hospital, DN                      268  6%                    302  6%                    366  6% 
St. Vincent’s Private Hospital, DN                      140  3%                    189  4%                    336  5% 
Tallaght Regional Hospital, DN                        40  1%                    215  4%                    314  5% 
University College Hospital , GY                      178  4%                    225  4%                    309  5% 
St. Vincent’s University Hospital, DN                      202  5%                    202  4%                    294  5% 
Mater Misericordiae University Hospital, DN                      204  5%                    235  5%                    278  4% 
Bon Secours Hospital , CK                      108  2%                    157  3%                    251  4% 
Mercy University Hospital, CK                      157  4%                    166  3%                    230  4% 
Mid-Western Regional Hospital, LK                      129  3%                    156  3%                    228  4% 
Cork University Hospital, CK                      159  4%                    156  3%                    208  3% 
Sligo General Hospital, SO                      111  2%                    169  3%                    200  3% 
Our Lady of Lourdes Hospital, LH                        92  2%                    130  3%                    190  3% 
Letterkenny General Hospital, DL                      190  4%                    218  4%                    184  3% 
Mayo General Hospital, MO                      138  3%                    137  3%                    180  3% 
Connolly Memorial Hospital, DN                        83  2%                    111  2%                    167  3% 
Kerry General Hospital, KY                      135  3%                      95  2%                    150  2% 
Wexford General Hospital, WX                      107  2%                    120  2%                    147  2% 
Waterford Regional Hospital, WD                      116  3%                    131  3%                    144  2% 
South Infirmary Hospital, CK                      100  2%                      91  2%                    134  2% 
Cavan General Hospital, CN                        87  2%                      75  1%                    124  2% 
Midland Regional Hospital, WH                        91  2%                      95  2%                    124  2% 
St. Luke’s General Hospital, KK                        77  2%                    135  3%                    113  2% 
Midland Regional Hospital , OY                        67  2%                      93  2%                    103  2% 
Other hospitals                   1,220  27%                1,131  23%                1,134  18% 
‡Counts of surgical resections performed up to one year after diagnosis in patients with invasive colorectal cancer, by hospital 
(Appendix II: treatment definitions). Figures include multiple resections performed on the same patient  
 
Surgical resections within one year of diagnosis were considered to be part of the primary course of treatment. The number of 
such colon cancer resections (C18) performed is presented for each diagnostic period, by hospital, in Table 24. The hospitals 
listed may have carried out further surgical procedures after the 1st anniversary of diagnosis, but these were not counted. 
Hospitals with less than 2% of the national caseload in the period 2005-2009 are not listed individually. 
The bulk of colorectal surgery (82%) was carried out in 24 hospitals during 2005-2009. St James’s Hospital, DN accounted for 7% 
of cases in 2005-2009. Other hospitals with more than 5% of cases in 2005-2009 were: Beaumont Hospital, DN (6%), St. 
Vincent’s Private Hospital, DN (5%), Tallaght RH, DN (5%), University College Hospital, GY (5%) and St. Vincent’s UH, DN (5%).  
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Table 25 
Surgical caseload by hospital: Diagnostic periods 1995-1999, 2000-2004, 2005-2009 
Tumours originating in the rectosigmoid junction and rectum (C19-20)  
 1995-1999 2000-2004 2005-2009 
 resections ‡ % resections ‡ % resections ‡ % 
Total                2,550  100%                2,844  100%                3,216  100% 
St. James’s Hospital, DN                    143  6%                    141  5%                    247  8% 
Tallaght Regional Hospital, DN                      37  1%                    127  4%                    227  7% 
St. Vincent’s Private Hospital, DN                    114  4%                    134  5%                    207  6% 
Beaumont Hospital, DN                    163  6%                    168  6%                    175  5% 
University College Hospital , GY                    145  6%                    152  5%                    174  5% 
St. Vincent’s University Hospital, DN                      81  3%                      92  3%                    151  5% 
Mercy University Hospital, CK                    138  5%                    147  5%                    139  4% 
Cork University Hospital, CK                      70  3%                    125  4%                    130  4% 
Mater Misericordiae University Hospital, DN                    180  7%                    144  5%                    130  4% 
Bon Secours Hospital, CK                      53  2%                      93  3%                    121  4% 
Mid-Western Regional Hospital, LK                      67  3%                      82  3%                    116  4% 
Sligo General Hospital, SO                      47  2%                      67  2%                    112  3% 
Connolly Memorial Hospital, DN                      75  3%                      71  2%                    110  3% 
Mayo General Hospital, MO                      99  4%                      88  3%                      93  3% 
Kerry General Hospital, KY                      52  2%                      71  2%                      82  3% 
St. Luke’s General Hospital, KK                      52  2%                      44  2%                      81  3% 
Our Lady of Lourdes Hospital, LH                      54  2%                      88  3%                      76  2% 
Wexford General Hospital, WX                      30  1%                      74  3%                      76  2% 
Letterkenny General Hospital, DL                      69  3%                      82  3%                      74  2% 
Waterford Regional Hospital, WD                      71  3%                      87  3%                      65  2% 
Cavan General Hospital, CN                      48  2%                      66  2%                      62  2% 
Midland Regional Hospital , OY                      29  1%                      46  2%                      52  2% 
Other hospitals                    695  27%                    604  21%                    470  15% 
‡Counts of surgical resections performed up to one year after diagnosis in patients with invasive colorectal cancer, by hospital 
(Appendix II: treatment definitions). Figures include multiple resections performed on the same patient  
 
The annual average number of rectal cancer resections (C18-20) performed is presented for each diagnostic period, by hospital, 
in Table 25. The hospitals listed may have carried out further surgical procedures after the 1st anniversary of diagnosis, but 
these were not counted.  The bulk of colorectal surgery (85%) was carried out in 22 hospitals during 2005-2009. St James’s 
Hospital, DN accounted for 8% of cases in 2005-2009. Other hospitals with more than 5% of cases in 2005-2009 were: Tallaght 
RH (7%), St. Vincent’s Private Hospital (6%), Beaumont Hospital, DN (5%), University College Hospital, GY (5%) and St. Vincent’s 
UH, DN (5%).  The proportion of patients who received rectal surgery in hospitals other than those listed decreased from 27% in 
1995-1999, to 15% in the most recent period (2005-2009). It appeared that a process of centralisation of rectal surgery services 
occurred, to some extent.  
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 3.6 Hospital caseload: radiotherapy 
Radiotherapy sessions administered within one year of diagnosis were considered to be part of the primary course of 
treatment. The annual average number of radiotherapy sessions is presented for each diagnostic period, by hospital, in Table 
26.  The hospitals shown may have administered further radiotherapy after the 1st anniversary of diagnosis, but these sessions 
were not counted. The bulk of radiotherapy services for colorectal cancer (91%) was provided by six hospitals over the period 
2005-2009.  St Luke’s Hospital provided most radiotherapy sessions, albeit this share fell from 67% in 1995-1999 to 39% in 
2005-2009. This fall may be accounted for by the introduction of radiotherapy at UCH Galway (12%) and the Mid-Western 
Radiation Oncology centre, LK (6%).  
 
3.7 Hospital: length of stay after colorectal surgery 
 
Table 27   
Median and inter-quartile range (IQR) length-of-stay (LOS) for colorectal cancer patients (C18-20) having resection 2002-2008 
and likelihood of prolonged length of stay (n=8,197) 39 
Type of admission for index surgical resection Elective  
surgery 
(n=5,133, 63%) 
Emergency  
surgery 
(n=3,064, 37%) 
 days [IQR] days [IQR] 
Median LOS (days) 14 [11-20] 21 [15-33] 
Predictors of prolonged LOS 
(>24 days in hospital) 
likelihood of prolonged LOS likelihood of prolonged LOS 
 Age >60 years (vs. <60 year) ↑  ↑  
 other marital status (vs. married) ↑  ↑  
 higher co-morbidity score ↑  ↑  
 private patient (vs. public patient) ↓  ↓  
 discharge to step-down care (vs. home) ↑  ↑  
 higher hospital caseload volume -  ↓  
↑= significantly greater likelihood of >24 days spent in hospital after surgery 
↓= significantly lesser likelihood of >24 days spent in hospital after surgery 
39 Kelly et al, BMC Health Services Research (2012) 12:77 
 
 A recent study using a National Cancer Registry dataset of colorectal cancer patients calculated length-of-stay (LOS) in hospital 
after the index cancer resection procedure.39 Incident colorectal cancers (C18-20), diagnosed 2002-2008, were identified from 
the NCR database, and linked to hospital in-patient episodes (HIPE).40   
 
Table 26 
Radiotherapy caseload by hospital: colorectal cancer (C18-20) 
Diagnostic periods: 1995-1999, 2000-2004,  2005-2009 
Diagnostic period 1995-1999 2000-2004 2005-2009 
 sessions‡ % sessions‡ % sessions‡ % 
Total 1,089 100% 1,581 100% 1,816 100% 
St. Luke’s Hospital, DN 728 67% 997 63% 701 39% 
Cork University Hospital, CK 174 16% 307 19% 324 18% 
University College Hospital, GY - - 4 <1% 219 12% 
Mater Private Hospital, DN 96 9% 151 10% 148 8% 
Mid–Western Radiation Oncology Centre, LK - - - - 142 8% 
St. Vincent’s Private Hospital, DN 85 8% 112 7% 104 6% 
Other private hospitals 1 <1% 8 1% 170 9% 
Other clinics 5 <1% 2 <1% 8 <1% 
‡Counts of radiotherapy sessions administered within 1 year of diagnosis, by hospital (Appendix II: treatment definitions).   
Figures include multiple sessions administered to the same patient, up to one year after diagnosis.   
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For those who underwent colorectal resection, the associated hospital episode was identified. Factors predicting prolonged LOS 
(>24 days) for elective and emergency procedures, were investigated (Table 27). 8,197 patients underwent resection, 63% (n = 
5,133) elective and 37% (n = 3,063) emergency admissions. Median LOS was 14 days (inter-quartile range (IQR) = 11-20) for 
elective and 21 (IQR=15-33) for emergency admissions. For both emergency and elective admissions, likelihood of longer LOS 
was significantly higher in patients who were older, had co-morbidities and were unmarried; it was reduced for private patients 
(Table 27).  
 
For emergency patients, the likelihood of longer LOS was lower for patients admitted to higher-volume hospitals. This study 
showed that 25% of patients stayed in hospital for at least >24 days following colorectal resection. Over one third of resected 
patients were emergency admissions and these had a significantly longer median LOS. Longer LOS was also associated with 
increased risk of emergency readmission within 28 days after discharge. Considering that the management of each case of 
colorectal cancer is estimated to cost around €40,000 38 (with hospital care accounting for much of this), the cost implications 
of prolonged LOS are significant. 
 
3.8 Colon cancer: factors associated with receipt of treatment  
The patient and tumour factors associated with tumour directed treatment were identified and are presented in Tables 28-37.  
Treatment was defined as receipt of any: surgery, radiotherapy, chemotherapy within one year of diagnosis date. A risk ratio 
(RR) less than 1.0 indicates a lesser likelihood of treatment relative to the baseline level of a variable (1.0). Similarly, a risk ratio 
greater than 1.0 indicates a greater likelihood of treatment after adjusting for the other variables in the models. 
 
Most patients (95%) presenting with stage II/III disease received surgery as first line treatment in 1995-1999, 2000-2004, 2005-
2009; there was no change in the proportion in receipt of surgery over the three diagnostic periods (Table 28). Adjuvant 
chemotherapy became an important part of the 
patient management in more recent years. Cases 
diagnosed during 2005-2009 were more likely to 
receive adjuvant chemotherapy compared to 
cases diagnosed during 1995-1999 (42% vs. 33% 
respectively, RR=1.33 95%CI: 1.23, 1.44) (Table 
28).  
 
 
 
 
 
 
 
Table 28 
Diagnostic period and treatment modalities in colon cancer (C18):  
Cases diagnosed at stage II/III 
period  SURGERY   SURGERY and
ADJUVANT CHEMOTHERAPY
 Cases T% RR 95%CI p T% RR 95%CI p
1995-1999 3,009 94% 1.00   33% 1.00  
2000-2004 3,274 94% 1.00 [0.95,1.05]  40% 1.29 [1.19,1.40] ***
2005-2009 4,042 95% 1.00 [0.95,1.05]  42% 1.33 [1.23,1.44] ***
total 10,325 95%    39% 
T%: Percentage treated 
RR: Risk ratios were adjusted for age, sex, stage, grade, deprivation,  
HSE area of residence.  * p<0.05, **p<0.001, *** p<0.0001 
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The proportion in receipt of surgery fell from 99% of 
cases under 45 years, to 92% of cases older than 75 
years (Table 29).  The proportion of patients who 
received adjuvant chemotherapy fell steadily from 
78% of patients less than 45 years,  to only 13% of 
patients older than 75 years (RR=0.17  95%CI: 0.15, 
0.20) (Table 29).  
 
 
 
The proportion in receipt of surgery was the same for 
males and females. A marginally higher proportion of 
males (40%) with colon cancer received adjuvant 
chemotherapy compared to females (37%), but the 
difference was not significant (RR=1.02, 95%CI: 0.95, 
1.08) (Table 30). 
 
 
 
Receipt of surgery or adjuvant chemotherapy was 
not dependent on the deprivation quintile of 
patient’s area of residence (Table 31). 
 
 
 
 
 
 
 
 
 
 
Table 29 
Age and treatment modalities in colon cancer (C18):  
Diagnostic period: 1995-2009.  Cases diagnosed at stage II/III 
age  SURGERY   SURGERY and
ADJUVANT CHEMOTHERAPY
 Cases T% RR 95%CI p T% RR 95%CI p 
15-44 347 99% 1.00   78% 1.00   
45-54 863 97% 0.97 [0.86,1.10]  69% 0.91 [0.79,1.05]  
55-64 2,028 96% 0.97 [0.87,1.09]  61% 0.81 [0.71,0.93] ** 
65-74 3,253 95% 0.96 [0.86,1.08]  44% 0.59 [0.51,0.67] ***
75+ 3,834 92% 0.94 [0.84,1.05]  13% 0.17 [0.15,0.20] ***
total 10,325 95%    39%    
T%: Percentage treated 
RR: Risk ratios were adjusted for sex, stage, grade, deprivation,  
HSE area of residence.  * p<0.05, **p<0.001, *** p<0.0001 
Table 30 
Gender and treatment modalities in colon cancer (C18):  
Diagnostic period: 1995-2009.  Cases diagnosed at stage II/III 
sex  SURGERY   SURGERY and
ADJUVANT CHEMOTHERAPY
 Cases T% RR 95%CI p T% RR 95%CI p
females 4,838 94% 1.00   37% 1.00  
males 5,487 95% 1.00 [0.96,1.04]  40% 1.02 [0.95,1.08] 
total 10,325 95%    39% 
T%: Percentage treated 
RR: Risk ratios were adjusted for age, stage, grade, deprivation,  
HSE area of residence.  * p<0.05, **p<0.001, *** p<0.0001 
Table 31 
Deprivation and treatment modalities in colon cancer (C18):  
Diagnostic period: 1995-2009.  Cases diagnosed at stage II/III 
deprivation  SURGERY   SURGERY and
ADJUVANT CHEMOTHERAPY
 Cases T% RR 95%CI p T% RR 95%CI p
least 2,082 95% 1.00   38% 1.00  
2 1,435 95% 1.00 [0.93,1.07]  40% 1.02 [0.92,1.14] 
3 1,376 95% 1.00 [0.93,1.08]  39% 1.05 [0.94,1.17] 
4 1,742 94% 1.00 [0.94,1.07]  39% 1.04 [0.94,1.15] 
most 3,149 94% 0.99 [0.94,1.05]  39% 1.04 [0.95,1.14] 
unknown 541 96% 1.01 [0.92,1.11]  40% 1.03 [0.88,1.19] 
total 10,325 95%    39% 
T%: Percentage treated 
RR: Risk ratios were adjusted for age, sex, stage, grade,  
HSE area of residence.  * p<0.05, **p<0.001, *** p<0.0001 
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Receipt of surgery or adjuvant chemotherapy 
was not dependent on the patient’s HSE area 
of residence (Table 32). 
 
 
 
 
 
 
3.9 Rectal cancer: Factors associated with receipt of treatment  
Pre-operative radiotherapy has been recommended for resectable rectal cancer in recent years.45,46   Factors affecting receipt of 
this treatment were explored (Tables 33-37).   Most patients (89%) presenting with stage II/III rectal cancer received surgery as 
first line treatment during the periods: 1995-
1999, 2000-2004, 2005-2009 (Table 33). Pre-
operative radiotherapy became an important 
part of patient management after 2000. 
Cases diagnosed during 2005-2009 were 
more likely to receive pre-operative 
radiotherapy compared to cases diagnosed 
during 1995-1999 (5% vs. 38% respectively). 
RR=7.59 95%CI: 5.87, 9.82) (Table 33).  
 
The proportion of patients in receipt of 
surgery decreased from 95% for cases <45 
years, to 81% for cases > 75 years (Table 34).  
The proportion of patients who received pre-
operative radiotherapy decreased from 31% 
for patients < 45 years, to only 12% for 
patients > 75 years (RR=0.32  95%CI: 0.24, 
0.44) (Table 34).  
 
 
 
 
 
Table 32 
HSE area and treatment modalities in colon cancer (C18):  
Diagnostic period: 1995-2009.  Cases diagnosed at stage II/III 
HSE 
area 
 SURGERY   SURGERY and 
ADJUVANT CHEMOTHERAPY 
 Cases T% RR 95%CI p T% RR 95%CI p
DNML 2,951 95% 1.00   37% 1.00  
DNNE 1,920 95% 1.00 [0.94,1.06]  37% 0.98 [0.89,1.08] 
South 2,764 95% 1.00 [0.95,1.06]  41% 1.09 [1.00,1.18] 
West 2,690 94% 1.01 [0.95,1.06]  40% 1.05 [0.97,1.15] 
total 10,325 95%    39%
T%: Percentage treated 
RR: Risk ratios were adjusted for age, sex, stage, deprivation.  
* p<0.05, **p<0.001, *** p<0.0001 
Table 33 
Diagnostic period and treatment modalities in rectal cancer (C19-20):  
Cases diagnosed at stage II/III 
period  SURGERY   SURGERY and PRE-OPERATIVE
RADIOTHERAPY 
±(neo-) adjuvant CHEMOTHERAPY
 Cases T% RR 95%CI p T% RR 95%CI p
1995-1999 1,485 91% 1.00   5% 1.00  
2000-2004 1,775 88% 0.96 [0.89,1.03]  21% 4.13 [3.16,5.40] ***
2005-2009 1,986 89% 0.96 [0.90,1.03]  38% 7.59 [5.87,9.82] ***
total 5,246 89%    23% 
T%: Percentage treated 
RR: Risk ratios were adjusted for age, sex, stage, grade, deprivation,  
HSE area of residence.  p: * p<0.05, **p<0.001, *** p<0.0001 
Table 34 
Age and treatment modalities in rectal cancer (C19-20):  
Diagnostic period: 1995-2009.  Cases diagnosed at stage II/III 
age  SURGERY   SURGERY and PRE-OPERATIVE
RADIOTHERAPY 
±(neo-) adjuvant CHEMOTHERAPY 
 Cases T% RR 95%CI p T% RR 95%CI p
15-44 206 95% 1.00   31% 1.00  
45-54 580 94% 0.98 [0.83,1.15]  33% 0.98 [0.73,1.31]  
55-64 1,221 93% 0.97 [0.84,1.13]  27% 0.82 [0.63,1.09]  
65-74 1,683 91% 0.95 [0.82,1.10]  23% 0.69 [0.53,0.91] ** 
75+ 1,556 81% 0.86 [0.74,0.99] * 12% 0.32 [0.24,0.44] ***
total 5,246 89%    23% 
T%: Percentage treated 
RR: Risk ratios were adjusted for sex, stage, grade, deprivation,  
HSE area of residence.  p: * p<0.05, **p<0.001, *** p<0.0001 
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There was no difference between males and 
females in the receipt of surgery (Table 35). 
However, males were significantly more likely 
to receive pre-operative radiotherapy (25% vs. 
19% for males and females respectively, 
RR=1.25 95%CI: 1.10, 1.43) (Table 35).  
 
 
 
Receipt of surgery, or pre-operative 
radiotherapy was not dependent on the 
deprivation quintile of patient’s area of 
residence (Table 36). 
 
 
 
 
 
 
 
HSE area of residence had no influence on 
whether a patient received surgery (Table 
37). However, patients from HSE South (22%) 
were marginally less likely to receive pre-
operative radiotherapy relative to patients 
within HSE DNML (25%), (South vs. DNML, 
RR=0.83 95%CI: 0.70, 0.97). 
 
 
 
 
 
Table 35 
Gender and treatment modalities in rectal cancer (C19-20):  
Diagnostic period: 1995-2009.  Cases diagnosed at stage II/III 
gender  SURGERY   SURGERY and PRE-OPERATIVE
RADIOTHERAPY 
±(neo-) adjuvant CHEMOTHERAPY
 Cases T% RR 95%CI p T% RR 95%CI p
females 1,848 88% 1.00   19% 1.00
males 3,398 89% 1.01 [0.95,1.07]  25% 1.25 [1.10,1.43] ***
total 5,246 89%    23% 
T%: Percentage treated 
RR: Risk ratios were adjusted for age, stage, grade, deprivation and 
HSE area of residence.  p: * p<0.05, **p<0.001, *** p<0.0001 
Table 36 
Deprivation and treatment modalities in rectal cancer (C19-20):  
Diagnostic period: 1995-2009.  Cases diagnosed at stage II/III 
Depriv- 
ation 
 SURGERY   SURGERY and PRE-OPERATIVE
RADIOTHERAPY 
±(neo-) adjuvant CHEMOTHERAPY
 Cases T% RR 95%CI p T% RR 95%CI p
least 1,038 89% 1.00   23% 1.00
2 738 91% 1.02 [0.92,1.12]  22% 1.13 [0.92,1.39]  
3 711 89% 1.00 [0.90,1.10]  25% 0.94 [0.75,1.18]  
4 883 90% 1.01 [0.91,1.11]  20% 1.03 [0.84,1.26]  
most 1,610 88% 0.98 [0.90,1.07]  22% 1.09 [0.92,1.30]  
unknown 266 90% 1.03 [0.89,1.18]  23% 1.21 [0.91,1.61]  
total 5,246 89%    23% 
T%: Percentage treated 
RR: Risk ratios were adjusted for age, sex, stage, grade and 
HSE area of residence.  p: * p<0.05, **p<0.001, *** p<0.0001 
Table 37 
HSE area of residence and treatment modalities in rectal cancer (C19-20) 
Diagnostic period: 1995-2009.  Cases diagnosed at stage II/III 
HSE 
area 
 SURGERY   SURGERY and PRE-OPERATIVE
RADIOTHERAPY 
±(neo-) adjuvant CHEMOTHERAPY
 Cases T% RR 95%CI p T% RR 95%CI p
DNML 1,395 88%    25%
DNNE 1,006 89% 1.02 [0.94,1.11]  22% 0.88 [0.74,1.06]  
South 1,481 90% 1.03 [0.95,1.11]  22% 0.83 [0.70,0.97] * 
West 1,364 89% 1.04 [0.95,1.12]  22% 0.86 [0.72,1.01]  
total 5,246 89%    23%
T%: Percentage treated 
RR: Risk ratios were adjusted for age, sex, stage, grade, deprivation 
p: * p<0.05, **p<0.001, *** p<0.0001 
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4.  SURVIVAL  
4.1 Comparison of survival  
 
Observed survival is simply the proportion remaining alive after a given period of time. Relative survival (RS) is the ratio of the 
observed survival proportion for a given group of cancer cases to the expected survival proportion of a group of individuals 
with the same demographic attributes. In practice, relative survival is similar to cause-specific survival—it measures the excess 
mortality due specifically to the cancer, and so is always greater than observed survival. Relative survival is now used by most 
cancer registries in place of cause specific survival because the actual cause of death in any given cancer case is not always 
known. Relative survival also facilitates international comparison, as it reduces problems related to international inconsistency 
in coding cause of death. Autopsy-only cases, DCO cases, colorectal cancers concurrent with another invasive malignancy and 
colorectal cancers incident during 2009 and 2010 were excluded for survival analysis (Table 47). 
 
Figure 13 
Percentage relative survival for invasive colorectal cancer (C18-C20), by gender and site of primary tumour 
Diagnostic period: 1994-1998, 1999-2003, 2004-2008 
MALES FEMALES 
period relative survival at: 1-yr% 95%CI 5-yr% 95%CI
1994-1998 colon (C18) 69 [67,71] 50 [48,53]
1999-2003 colon (C18) 71 [69,73] 52 [50,55]
2004-2008 colon (C18) 77 [75,78] 58 [56,61]
1994-1998 rectum (C19-20) 72 [70,74] 46 [43,48]
1999-2003 rectum (C19-20) 75 [73,77] 51 [48,53]
2004-2008 rectum (C19-20) 81 [79,82] 55 [52,59]
 
period relative survival at: 1-yr% 95%CI 5-yr% 95%CI
1994-1998 colon (C18) 68 [66,70] 52 [49,54]
1999-2003 colon (C18) 70 [69,72] 54 [52,56]
2004-2008 colon (C18) 73 [71,75] 59 [56,62]
1994-1998 rectum (C19-20) 74 [71,77] 52 [49,56]
1999-2003 rectum (C19-20) 72 [69,75] 55 [52,59]
2004-2008 rectum (C19-20) 80 [78,83] 61 [57,65]
 
In colon cancer, 1 year survival improved by 8 percentage points (69-77%) for males and 5 points (68-73%) for females between 
the periods 1994-1998 and 2004-2008. The improvement was maintained at 5 years; 8 points (50-58%) for males and 7 points 
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(52-59%) for females.  The scale of the improvement in survival in colon cancer, between the earlier and later periods (1994-
1998 and 2004-2008) was greater for males, at 1 year and 5 years (Figure 13).  
In rectal cancer, 1 year survival improved by 9 points (72-81%) for males and 6 points (74- 80%) for females between the 
periods 1994-1998 and 2004-2008. The improvement was maintained at 5 years; 9 points (46-55%) for males and 9 points (52-
61%) for females.  The scale of the improvement in survival at 1 year for rectal cancer, between the earlier and later periods 
(1994-1998 and 2004-2008) was greater for males (Figure 13). 
 
Figure 14 
Percentage relative survival for invasive colorectal cancer (C18-C20), by gender, age and site of primary tumour 
Diagnostic periods: 1994-1998 and  2004-2008 
MALES FEMALES 
site relative 
survival at: 
age 1-yr% 95%CI 5-yr% 95%CI
colon (C18) 1994-1998 <70yr 75 [73,78] 52 [49,55]
colon (C18) 1994-1998 70+yr 63 [60,65] 48 [44,52]
colon (C18) 2004-2008 <70yr 85 [83,87] 62 [59,65]
colon (C18) 2004-2008 70+yr 69 [66,71] 54 [49,58]
rectum (C19-20) 1994-1998 <70yr 77 [74,79] 46 [42,49]
rectum (C19-20) 1994-1998 70+yr 66 [62,69] 45 [41,50]
rectum (C19-20) 2004-2008 <70yr 87 [85,89] 58 [54,62]
rectum (C19-20) 2004-2008 70+yr 72 [68,75] 51 [45,57]
 
site relative
survival at:
age 1-yr% 95%CI 5-yr% 95%CI
colon (C18) 1994-1998 <70yr 78 [76,81] 55 [51,58]
colon (C18) 1994-1998 70+yr 60 [57,63] 49 [45,52]
colon (C18) 2004-2008 <70yr 85 [83,87] 63 [60,67]
colon (C18) 2004-2008 70+yr 63 [61,66] 53 [50,57]
rectum (C19-20) 1994-1998 <70yr 84 [81,87] 58 [53,62]
rectum (C19-20) 1994-1998 70+yr 65 [60,69] 45 [40,51]
rectum (C19-20) 2004-2008 <70yr 91 [89,93] 70 [65,74]
rectum (C19-20) 2004-2008 70+yr 69 [65,73] 51 [44,57]
 
In colon cancer, in the under 70 years subset, 1 year survival improved by 10 points (75-85%) for males and 7 points (78- 85%) 
for females between the periods 1994-1998 and 2004-2008. The improvement was maintained at 5 years; 10 points (52-62%) 
for males and 8 points (55-63%) for females. In the greater than 70 years subset, I year survival improved by 6 points (63%-69%) 
in males and 3 points in females (60-63%). The improvement was maintained at 5 years; 6 points (48-54%) in males and 4 
points (49-53%) in females. The scale of the improvement in survival between the earlier and later periods (1994-1998 and 
2004-2008) in colon cancer was greater for males (Figure 14).  
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In rectal cancer, in the less than 70 years subset, 1 year survival improved by 10 points (77-87%) for males and 7 points (84-
91%) for females between the periods 1994-1998 and 2004-2008. The improvement was maintained at 5 years; 12 points (46-
58%) for males and 12 points (58-70%) for females. In the greater than 70 years subset, I year survival improved by 6 points 
(66%-72%) in males and 4 points in females (65-69%). The improvement was maintained at 5 years; 6 points (45-51%) in males 
and 6 points (45-51%) in females. For survival at 1 year, the scale of the improvement in survival between the earlier and later 
periods (1994-1998 and 2004-2008) in rectal cancer was greater for males; at five years the scale of the improvement was 
similar for males and females (Figure 14).  
 
 
For colon cancer patients presenting at stage I, relative survival at 5 years was high, ranging from 90% for cases presenting in 
1994-1998, to 95% for cases presenting in 2004-2008 (an improvement of 5 percentage points). For stage II patients, relative 
survival at 5 years increased from 70% during the period 1994-1998, to 83% during 2004-2008 (an improvement of 13 
percentage points). For stage III patients, relative survival at 5 years increased from 47% during the period 1994-1998, to 64% 
during 2004-2008 (an improvement of 17 percentage points). For stage IV patients, there was no change in relative survival at 
five years (<10% for each of the periods: 1994-1998, 1999-2003, and 2004-2008). However, 1 year survival for stage IV patients 
did improve from 31% during 1994-1998 to 43% during 2004-2008 (an improvement of 12 percentage points) (Figure 15).  
 
 
 
Figure 15 
Percentage relative survival for colon cancer (C18), by stage of disease 
Diagnostic periods: 1994-1998, 1999-2003, 2004-2008 
stage relative survival at: 1-yr% 95%CI 5-yr% 95%CI
stage I 1994-1998 95 [92,97] 90 [85,94]
stage I 1999-2003 95 [92,97] 92 [87,96]
stage I 2004-2008 96 [93,98] 95 [89,99]
stage III 1994-1998 78 [75,80] 47 [44,51]
stage III 1999-2003 82 [80,84] 56 [53,60]
stage III 2004-2008 85 [83,87] 64 [61,68]
 
stage relative survival at: 1-yr% 95%CI 5-yr% 95%CI
stage II 1994-1998 85 [83,87] 70 [67,73]
stage II 1999-2003 86 [84,88] 75 [72,78]
stage II 2004-2008 88 [86,89] 83 [79,86]
stage IV 1994-1998 31 [28,34] 8 [6,10]
stage IV 1999-2003 36 [33,39] 8 [6,9]
stage IV 2004-2008 43 [41,46] 9 [7,12]
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For rectal cancer patients presenting at stage I, relative survival at 5 years was high, ranging from 82% for cases presenting in 
1994-1998, to 92% for cases presenting in 2004-2008 (an improvement of 10 percentage points). For stage II patients, relative 
survival at 5 years increased from 58% during the period 1994-1998, to 70% during 2004-2008 (an improvement of 12 
percentage points). For stage III patients, relative survival at 5 years increased from 45% during the period 1994-1998, to 64% 
during 2004-2008 (an improvement of 19 percentage points). For stage IV patients, relative survival at 5 years increased from 
7% during the period 1994-1998, to 10% during 2004-2008 (an improvement of 3 percentage points). Relative survival at 1 year 
for stage IV patients improved from 35% during 1994-1998 to 51% during 2004-2008 (an improvement of 16 percentage points) 
(Figure 16). 
 
 
 
 
 
 
 
 
 
 
Figure 16 
Percentage relative survival for rectal cancer (C19-20), by stage of disease 
Diagnostic periods: 1994-1998, 1999-2003, 2004-2008 
stage relative survival at: 1-yr% 95%CI 5-yr% 95%CI
stage I 1994-1998 92 [90,95] 82 [77,86]
stage I 1999-2003 94 [91,96] 87 [82,91]
stage I 2004-2008 96 [93,98] 92 [86,97]
stage III 1994-1998 85 [82,88] 45 [40,49]
stage III 1999-2003 87 [84,89] 54 [50,58]
stage III 2004-2008 90 [88,92] 64 [59,69]
 
stage relative survival at: 1-yr% 95%CI 5-yr% 95%CI
stage II 1994-1998 82 [79,85] 58 [53,62]
stage II 1999-2003 81 [78,84] 65 [61,69]
stage II 2004-2008 88 [85,90] 70 [65,76]
stage IV 1994-1998 35 [31,38] 7 [5,9]
stage IV 1999-2003 41 [37,44] 10 [7,12]
stage IV 2004-2008 51 [48,55] 10 [7,14]
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1-year and 5-year cause specific survival was calculated by 
deprivation quintile (‘least’ and ‘most’ only) and diagnostic 
periods 1994-1998 and 2004-2008 (Figure 17).   
 
For females, in the earliest period (1994-1998), 5-year survival 
was notably lower (48%) in the most deprived quintile 
compared to least deprived quintile (54%). The difference in 
survival between these quintiles increased from 6% in 1994-
1998 to 7% in 2004-2008.   
 
By contrast, for men, in the earliest period (1994-1998), 5-year 
survival was 43% in the most deprived quintile compared 49% 
to least deprived quintile. The difference in survival between 
these quintiles decreased from 6% in 1994-1998 to 4% in 
2004-2008.  
 
Therefore, for the two diagnostic periods examined, the 
differences in cancer survival associated with deprivation 
seemed to converge for males and diverge for females.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 
Cause specific survival for colorectal cancer (C18-20),   
by  gender  and deprivation (least and most) 
Diagnostic periods 1994-1998 & 2004-2008 
gender deprivation cause sp. 
 survival at 
1-yr% 95%CI 5-yr% 95%CI
males least 1994-1998 75 [72,77] 49 [45,52]
males most 1994-1998 69 [67,72] 43 [40,46]
males least 2004-2008 82 [80,84] 58 [55,62]
males most 2004-2008 77 [75,79] 54 [50,57]
females least 1994-1998 75 [71,78] 54 [50,58]
females most 1994-1998 70 [67,72] 48 [45,51]
females least 2004-2008 79 [77,82] 62 [58,65]
females most 2004-2008 74 [72,77] 55 [51,58]
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4.2 Factors associated with cause-specific survival  
Survival analysis, stratified by age, gender, stage and site of tumour, was performed on colorectal cancer cases accrued over 
three diagnostic periods 1994-1998, 1999-2003 and 2004-2008. Cases were followed up until date of death (due to cancer) or 
censoring date (31/12/09), whichever occurred first.c  Adjusted (multivariate) Cox regression models of the effect of period of 
diagnosis on cause-specific overall survival were derived. Hazard ratios less than 1.0 indicate relatively improved survival when 
compared with the reference diagnostic period: 1994-1998.  
 
While the percentage cause specific survival at 5 years is 57% for both colon and rectal cancer, rectal cancer showed marginally 
poorer survival for all patients accrued during the period 1994-2008 (HR=1.04 95%CI: 1.01, 1.08) (Table 38).  
 
 
Table 39 
Cancer cause-specific survival in patients with colorectal cancer  (C18-20): ALL STAGES,  ALL AGES, MALES AND FEMALES 
Percentage survival at 1-year, adjusted hazard ratios, by diagnostic period and site of primary tumour 
period site ‡No. ‡1-yr% HR 95%CI p 
1994-1998 colon (C18)   5,306  72% 1.00   
1999-2003   5,417  73% 0.88 [0.83,0.93] *** 
2004-2008   6,363  77% 0.71 [0.68,0.76] *** 
1994-1998 rectum (C19-20)   3,048  75% 1.00   
1999-2003   3,290  76% 0.86 [0.80,0.92] *** 
2004-2008   3,493  82% 0.65 [0.60,0.70] *** 
‡ Total number of patients in category and percentage of those who survived cancer related death up to 1 year after diagnosis 
Models adjusted for age, sex, stage, grade of tumour, smoking status, marital status, HSE area of residence and deprivation 
p= *p<0.05, **p<0.001, ***p<0.0001 
HR=adjusted hazard ratio for cause specific survival (overall time to censoring date or cause specific death) 
While rectal cancer showed marginally poorer survival overall (Table 38), for the comparison between the earliest and latest 
diagnostic periods, the improvement in survival was greater for rectal cancer relative to colon cancer (Table 39); (HR=0.65 
95%CI: 0.60,0.70) vs. (HR=0.71 95%CI: 0.68,0.76),  for rectal and colon respectively. 
 
 
                                         
c Appendix II: Statistical methods 
Table 38 
Cancer cause-specific survival in patients  with colorectal cancer  (C18-20):  ALL STAGES and ALL AGES  
Diagnostic period: 1994-2008 
Percentage survival at 5 years, adjusted hazard ratios, by site of primary tumour 
Site ‡No. 5-yr%‡ HR 95%CI p 
colon (C18) 17,086 57% 1.00   
rectum (C19-20) 9,831 57% 1.04 [1.01,1.08] * 
total 26,917     
‡ Total number of patients in category and percentage of those who survived cancer related death up to 5 years after diagnosis 
Model adjusted for age, sex, stage, grade of tumour, smoking status, marital status, HSE area of residence and deprivation and 
diagnostic period. p= *p<0.05 
HR=adjusted hazard ratio for cause specific survival (overall time to censoring date or cause specific death) 
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For younger males (<70 years ) with stage II/III colon cancer, the proportion who survived cancer after one year increased 
incrementally from 88% in the earliest period (1994-1998), to 96% in the latest period (2004-2008) (HR=0.51 95%CI:0.42,0.62). 
There was also a simultaneous and incremental increase in survival for rectal cancer; starting from 89% during 1994-1998, to 
95% for the period 2004-2008 (HR=0.51 95%CI: 0.41, 0.63) (Table 40).  
 
For older males (>70 years) with colon cancer, there was a significant improvement in survival from 79% in the earliest period 
to 85% in the latest period (HR=0.67 95%CI: 0.57, 0.79).  There was also a simultaneous improvement in survival for older males 
with rectal cancer, starting from 80% in the earliest period to 86% in the latest period (HR=0.66 95%CI: 0.53, 0.81) (Table 40).  
 
These data show a highly significant improvement in cancer survival for males (<70 and >70 years) with colorectal cancer. The 
improved survival was probably due to greater uptake of treatment and earlier diagnosis.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 40 
Cancer cause-specific survival in patients  with stage II/III  colorectal cancer  (C18-20): MALES 
Percentage survival at 1-year, adjusted hazard ratios, by diagnostic period, age and site of primary tumour 
period age site ‡No. 1-yr%‡ HR 95%CI p 
1994-1998 
<7
0 
ye
ar
s 
colon (C18) 752 88% 1.00   
1999-2003 743 91% 0.73 [0.62,0.86] *** 
2004-2008 935 96% 0.51 [0.42,0.62] *** 
    
1994-1998 rectum (C19-20) 502 89% 1.00   
1999-2003 622 92% 0.69 [0.58,0.83] *** 
2004-2008 666 95% 0.51 [0.41,0.63] *** 
     
1994-1998 
70
+ 
ye
ar
s 
colon (C18) 763 79% 1.00   
1999-2003 801 81% 0.91 [0.79,1.06]  
2004-2008 1,014 85% 0.67 [0.57,0.79] *** 
    
1994-1998 rectum (C19-20) 428 80% 1.00   
1999-2003 462 82% 0.86 [0.71,1.03]  
2004-2008 488 86% 0.66 [0.53,0.81] *** 
‡ Total number of patients in category and percentage of those who survived cancer related death up to 1-year after diagnosis
Models adjusted for age, stage, grade of tumour, smoking status, marital status, HSE area of residence and deprivation 
p= *p<0.05, **p<0.001, ***p<0.0001 
HR=adjusted hazard ratio for cause specific survival (overall time to censoring date or cause specific death) 
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For younger females (<70 years ) with stage II/III colon cancer, the proportion who survived cancer after one year increased 
from 89% in the earliest period (1994-1998), to 94% in the latest period (2004-2008) (HR=0.53 95%CI:0.42,0.66). There was also 
a simultaneous increase in survival for rectal cancer; starting from 93% during 1994-1998, to 96% for the period 2004-2008 
(HR=0.58 95%CI: 0.41, 0.80) (Table 41). 
 
For older females (>70 years) with colon cancer, there was a modest improvement in survival from 78% in the earliest period to 
79% in the latest period (HR=0.82 95%CI: 0.70, 0.96).  For rectal cancer, the proportion who survived to one year increased 
from 77% in 1994-1998 to 81% in 2004-2008. However, the improvement was not statistically significant (HR=0.81 95%CI: 0.62, 
1.04). These data show a significant improvement in cancer survival for younger females (<70 years) with colon cancer. There 
was also an improvement in survival from rectal cancer in the latest period (2004-2008) (Table 41).   
 
In contrast with the data for older males (>70 years) (Table 40), older females showed only a modest improvement in survival 
for colon cancer, and no improvement for rectal cancer (Table 41).  
 
 
 
 
 
 
 
 
 
 
Table 41 
Cancer cause-specific survival in patients  with stage II/III  colorectal cancer  (C18-20): FEMALES 
Percentage survival at 1-year, adjusted hazard ratios, by diagnostic period, age and site of primary tumour 
period age site ‡No. ‡1-yr% HR 95%CI p 
1994-1998 
<7
0 
ye
ar
s 
colon (C18) 657 89% 1.00   
1999-2003 640 91% 0.76 [0.63,0.92] ** 
2004-2008 725 94% 0.53 [0.42,0.66] *** 
    
1994-1998 rectum (C19-20) 257 93% 1.00   
1999-2003 290 92% 0.86 [0.66,1.13]  
2004-2008 354 96% 0.58 [0.41,0.80] ** 
     
1994-1998 
70
+ 
ye
ar
s 
colon (C18) 734 78% 1.00   
1999-2003 834 79% 0.91 [0.79,1.05]  
2004-2008 973 79% 0.82 [0.70,0.96] * 
    
1994-1998 rectum (C19-20) 261 77% 1.00   
1999-2003 271 70% 1.05 [0.83,1.32]  
2004-2008 320 81% 0.81 [0.62,1.04]  
‡ Total number of patients in category and percentage of those who survived cancer related death up to 1-year after diagnosis
Models adjusted for age, stage, grade of tumour, smoking status, marital status, HSE area of residence and deprivation 
p= *p<0.05, **p<0.001, ***p<0.0001 
HR=adjusted hazard ratio for cause specific survival (overall time to censoring date or cause specific death) 
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For younger males (<70 years ) with stage IV colon cancer, the proportion who survived cancer after one year increased 
incrementally from 41% in the earliest period (1994-1998), to 58% in the latest period (2004-2008) (HR=0.67  95%CI:0.57, 0.79). 
There was also a simultaneous and incremental increase in survival for rectal cancer; starting from 42% during 1994-1998, to 
64% for the period 2004-2008 (HR=0.51 95%CI: 0.42, 0.62) (Table 42).  
 
For older males (>70 years) with stage IV colon cancer, there was no real improvement in survival across three diagnostic 
periods.  However, there was an improvement in survival for older males with rectal cancer, from 27% in the earliest period to 
38% in the latest period (HR=0.71 95%CI: 0.56, 0.89) (Table 42).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 42 
Cancer cause-specific survival in patients  with stage IV colorectal cancer  (C18-20): MALES 
Percentage survival at 1-year, adjusted hazard ratios, by diagnostic period, age and site of primary tumour 
period age site ‡No. ‡1-yr% HR 95%CI p 
1994-1998 
<7
0 
ye
ar
s 
colon (C18) 348 41% 1.00   
1999-2003 378 47% 0.84 [0.72,0.99] * 
2004-2008 401 58% 0.67 [0.57,0.79] *** 
       
1994-1998 rectum (C19-20) 236 42% 1.00   
1999-2003 250 49% 0.75 [0.61,0.91] ** 
2004-2008 299 64% 0.51 [0.42,0.62] *** 
        
1994-1998 
70
+ 
ye
ar
s 
colon (C18) 284 26% 1.00   
1999-2003 361 31% 0.97 [0.81,1.15]  
2004-2008 460 36% 0.85 [0.72,1.01]  
       
1994-1998 rectum (C19-20) 164 27% 1.00   
1999-2003 199 36% 0.80 [0.63,1.01]  
2004-2008 201 38% 0.71 [0.56,0.89] ** 
‡ Total number of patients in category and percentage of those who survived cancer related death up to 1-year after diagnosis
Models adjusted for age, stage, grade of tumour, smoking status, marital status, HSE area of residence and deprivation 
p= *p<0.05, **p<0.001, ***p<0.0001 
HR=adjusted hazard ratio for cause specific survival (overall time to censoring date or cause specific death) 
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For younger females (<70 years ) with stage IV colon cancer, the proportion who survived cancer after one year increased 
significantly from 45% in the earliest period (1994-1998), to 63% in the latest period (2004-2008) (HR=0.76  95%CI:0.62, 0.92). 
There was also a modest increase in survival for rectal cancer, starting from 51% during 1994-1998, to 71% for the period 2004-
2008 (HR=0.67 95%CI: 0.48, 0.94) (Table 43).  
 
For older females (>70 years) with stage IV colon cancer, there was no real improvement in survival across the three diagnostic 
periods.  However, there was an improvement in survival for rectal cancer, starting from 31% in the earliest period to 43% in 
the latest period (HR=0.66 95%CI: 0.49, 0.91) (Table 43).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 43 
Cancer cause-specific survival in patients  with stage IV colorectal cancer  (C18-20): FEMALES 
Percentage survival at 1-year, adjusted hazard ratios, by diagnostic period, age and site of primary tumour 
period age site ‡No. S‡1-yr% HR 95%CI p 
1994-1998 
<7
0 
ye
ar
s 
colon (C18) 242 45% 1.00   
1999-2003 257 47% 1.03 [0.84,1.25]  
2004-2008 329 63% 0.76 [0.62,0.92] ** 
       
1994-1998 rectum (C19-20) 94 51% 1.00   
1999-2003 89 52% 0.98 [0.69,1.37]  
2004-2008 113 71% 0.67 [0.48,0.94] * 
        
1994-1998 
70
+ 
ye
ar
s 
colon (C18) 292 28% 1.00   
1999-2003 305 33% 0.92 [0.77,1.10]  
2004-2008 355 30% 0.93 [0.78,1.10]  
       
1994-1998 rectum (C19-20) 101 31% 1.00   
1999-2003 106 38% 0.71 [0.52,0.97] * 
2004-2008 124 43% 0.66 [0.49,0.91] ** 
‡ Total number of patients in category and percentage of those who survived cancer related death up to 1-year after diagnosis
Models adjusted for age, stage, grade of tumour, smoking status, marital status, HSE area of residence and deprivation 
p= *p<0.05, **p<0.001, ***p<0.0001 
HR=adjusted hazard ratio for cause specific survival (overall time to censoring date or cause specific death) 
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4.3 International comparison of relative survival 
 
A comparison of 5-year period relative survival 
for colorectal cancer cases accrued during the 
years 2000-2002 is presented in Figure 18.24  
 
Across Europe, five-year relative survival from 
colorectal cancer for patients diagnosed in 2000-
2002 ranged from 45% in the Czech Republic to 
64% in Switzerland.  Survival in Ireland (54%) was 
similar to that of our nearest neighbours, England 
(52%), Scotland (54%), Wales (53%) and Northern 
Ireland (55%), and just below the European 
average (56%).  
 
Pooled 5-year relative survival estimates derived 
from 13 SEER registries in the United States was 
66%, which was significantly higher than 5-year 
survival for cases in Ireland during the same 
period (54%). 
 
Considering only the countries with national 
cancer registries, Iceland (59%), Sweden (60%), 
Finland (59%), Norway (60%) and the 
Netherlands (59%) all had significantly higher 
relative survival than Ireland while Malta (51%), 
Slovenia (51%), Poland (46%) and the Czech 
Republic (45%) all had marginally lower relative 
survival than Ireland.  
 
 
 
 
 
 
 
 
 
Figure 18 
Age adjusted 5-year relative survival of colorectal cancer 
Diagnosis period: 2000-2002 
(Eurocare-4. Verdecchia A, et al., 2007) 24 
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5.  MORTALITY 
Colorectal cancer was the third leading cause of cancer death in females in 2007-2009, after lung cancer and breast cancer, and 
the second leading cause of cancer death in males after lung cancer. It accounted for 10% and 12% of cancer deaths in males 
and females respectively in 2007.25 
5.1 Mortality trends 
 
Mortality data obtained from the CSO for the period 1994-2009 is presented in Tables 44-46. 36 
There were on average 400 female and 552 male deaths per year from colorectal cancer (C18-20) between 2005 and 2009.  For 
females, the age standardised rate (ASR) of mortality fell from 21/100,000 in 1994 to 14/100,000 in 2009, an annual decrease 
of 2.1%. For males, the ASR fell from 34/100,000 to 28/100,000 in 2009, an annual decrease of 1.6% (Table 44). 
 
Figure 19 
Age standardised rate (ASR): mortality 
colorectal cancer C18-C20:  1956-2009 
 
Table 44 
Age standardised rate (ASR): mortality 
colorectal cancer C18-C20:  1994-2009 
females males all 
year deaths ASR deaths ASR deaths ASR
1994  415 20.6  508  34.0  923 26.5
1995  424 21.0  550  35.8  974 27.6
1996  403 18.9  493  32.2  896 25.0
1997  443 21.5  528  33.7  971 26.9
1998  369 17.2  509  31.8  878 23.7
1999  409 18.9  561  35.1  970 26.1
2000  411 19.0  493  29.9  904 23.8
2001  359 16.1  564  33.9  923 23.8
2002  388 17.0  510  29.7  898 22.7
2003  426 18.3  492  28.1  918 22.7
2004  400 16.6  557  31.3  957 23.0
2005  402 16.8  532  28.5  934 21.8
2006  417 16.2  582  30.7  999 22.8
2007  377 15.3  533  27.3  910 20.5
2008  424 16.4  550  27.7  974 21.5
2009  381 14.1  564  27.5  945 20.2
total  6,448  8,526   14,974 
APC(94-09) -0.3% -2.1% 0.5% -1.6% 0.2% -1.8%
[ 9 5 % C I ] [-0.9,0.4] [-2.8,-1.4] [-0.1,1.1] [-2.2,-1.0] [-0.3,0.6] [-2.2,-1.4]
 
 
Gender Period APC [95%CI] trend 
Females 1956-1975 1.1% [0.6, 1.5%] ↑ 
 1976-2009 -2.0% [-2.2, -1.8%] ↓ 
Males 1956-1988 0.7% [0.5, 1.0%] ↑ 
 1989-2009 -1.3% [-1.8, -0.8%] ↓ 
 
Age standardised rates of mortality for colorectal cancer (C18-20) for the period 1956-2009 are presented in Figure 19.  A 
significant 1.1% annual percentage increase in the female mortality rate was observed from 1956 to 1975. Thereafter, there 
was a significant 2% annual decrease in mortality, from 1976 to 2009. A significant 0.7% annual percentage increase in the male 
mortality rate was observed from 1956 to 1988. Thereafter, there was a significant 1.3% annual decrease in mortality, from 
1989 to 2009.  
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Figure 20 
Age standardised rate (ASR): mortality 
colon cancer C18:  1956-2009 
 
Table 45 
Age standardised rate (ASR): mortality 
colon cancer C18:  1994-2009 
females males all 
year deaths ASR deaths ASR deaths ASR
1994  321 15.9  360 24.1  681 19.5
1995  331 16.4  397 25.5  728 20.5
1996  327 15.4  358 23.2  685 18.9
1997  342 16.7  385 24.7  727 20.2
1998  296 13.8  363 22.7  659 17.8
1999  315 14.2  391 24.3  706 18.8
2000  313 14.6  364 22.2  677 17.8
2001  264 11.7  367 22.1  631 16.2
2002  283 12.5  334 19.3  617 15.6
2003  313 13.2  293 16.7  606 14.9
2004  284 11.6  333 18.7  617 14.7
2005  268 10.9  317 16.9  585 13.4
2006  282 10.9  339 18.0  621 14.1
2007  213 8.4  298 15.3  511 11.4
2008  271 10.3  310 15.7  581 12.7
2009  240 8.5  302 14.8  542 11.3
total  4,663  5,511  10,174 
APC(94-09) -2.1% -4.2% -1.7% -3.7% -1.9% -3.9%
[ 9 5 % C I ] [-3.0,-1.2] [-5.1,-3.2] [-2.4,-1.0] [-4.4,-3.0] [-2.4,-1.3] [-4.5,-3.3]
 
 
Gender Period APC [95%CI] trend 
Females 1956-1974 1.3% [0.7, 2.0%] ↑ 
 1975-1997 -1.7% [-2.2, -1.2%] ↓ 
 1998-2009 -4.6% [-5.7, -3.4%] ↓ 
Males 1956-1995 1.0% [0.8, 1.2%] ↑ 
 1996-2009 -4.1% [-5.0, -3.1%] ↓ 
 
There were on average 255 female and 313 male deaths per year from colon cancer (C18) between 2005 and 2009.  For 
females, the age standardised rate (ASR) fell from 16/100,000 in 1994 to 9/100,000 in 2009, an annual decrease of 4.2%. For 
males, the ASR fell from 24/100,000 in 1994 to 15/100,000 in 2009, an annual decrease of 3.7% (Table 45). 
 
Age standardised rates of mortality for colon cancer (C18) for the period 1956-2009 are presented in Figure 20.  A significant 
1.3% annual percentage increase in the female mortality rate was observed from 1956 to 1974. Thereafter, there was a 
significant 1.7% annual decrease in mortality from 1975 to 1997, followed by another significant annual decrease of 4.6% from 
1998 to 2009.   A significant 1.0% annual percentage increase in the male mortality rate was observed from 1956 to 1995. 
Thereafter, there was a significant 4.1% annual percentage decrease in mortality from 1996 to 2009 (Figure 20).  
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Figure 21 
Age standardised rate (ASR): mortality 
 rectal cancer (C19-20): 1956-2009 
 
Table 46 
Age standardised rate (ASR): mortality 
rectal cancer C19-20:  1994-2009 
 females males all 
year deaths ASR deaths ASR deaths ASR
1994  94 4.8  148  9.9  242 7.0
1995  93 4.6  153  10.3  246 7.1
1996  76 3.6  135  8.9  211 6.0
1997  101 4.8  143  9.0  244 6.7
1998  73 3.3  146  9.1  219 5.9
1999  94 4.6  170  10.8  264 7.3
2000  98 4.5  129  7.8  227 6.0
2001  95 4.3  197  11.9  292 7.6
2002  105 4.4  176  10.4  281 7.2
2003  113 5.1  199  11.4  312 7.8
2004  116 5.0  224  12.7  340 8.3
2005  134 5.9  215  11.5  349 8.4
2006  135 5.3  243  12.7  378 8.7
2007  164 6.9  235  12.0  399 9.1
2008  153 6.2  240  12.1  393 8.8
2009  141 5.5  262  12.8  403 8.9
total  1,785  3,015    4,800 
APC(94-09) 4.4% 2.8% 4.6% 2.4% 4.5% 2.5%
[ 9 5 % C I ] [3.0,5.9] [1.2,4.4] [3.4,5.9] [1.1,3.6] [3.5,5.6] [1.5,3.5]
 
 
Gender Period APC [95%CI] trend 
Females 1956-1975 0.6% [-0.4, 1.5%] ↔ 
 1976-1998 -2.4% [-3.1, -1.6%] ↓ 
 1999-2009 4.7% [2.4, 7.0%] ↑ 
Males 1956-1976 0.6% [-0.3, 1.4%] ↔ 
 1977-1997 -1.5% [-2.3, -0.7%] ↓ 
 1998-2009 3.1% [1.3, 4.9%] ↑ 
 
There were on average 145 female and 239 male deaths per year from cancer of the rectosigmoid junction and rectum (C19-
20) between 2005 and 2009.  For females, the age standardised rate (ASR) of mortality increased from 4.8/100,000 in 1994 to 
5.5/100,000 in 2009, an annual increase of 2.8%. For males, the ASR increased from 9.9/100,000 in 1994 to 12.8/100,000 in 
2009, an annual increase of 2.4% (Table 46). 
 
Age standardised rates for colorectal cancer (C19-20) for the period 1956-2009 are presented in Figure 21.  There was a 0.6% 
annual percentage increase in female mortality rate from 1956 to 1975. Thereafter, there was a significant 2.4% annual 
decrease in mortality from 1976 to 1998, followed by a significant annual increase of 4.7% from 1999 to 2009.  For, males, a 
similar pattern was evident; a 0.6% annual percentage increase in mortality rate from 1956 to 1976. Thereafter, there was a 
significant 1.5% annual decrease in mortality from 1977 to 1997, followed by a significant annual increase of 3.1% from 1998 to 
2009 (Figure 21).  
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5.2 Age distribution of mortality 
 
 
The number of colorectal cancer deaths per year by age group over the periods 1994-2001 and 2002-2009 is presented in 
Figure 22a.36  For females, the number of deaths per year (75 per year) was highest in the 80-84 age group during 1994-2001 
and in the 85+ age group (85 per year) during 2002-2009. The peak age-specific mortality rate, which occurred in the 85+ age 
group in both periods, was 273/100,000 women during 1994-2001, and 256/100,000 women during 2002-2009 (Figure 22a). 
 
For males, the number of deaths per year (96 per year) was highest in the 70-74 age group during 1994-2001 and 2002-2009. 
The peak age-specific mortality rate, which occurred in the 85+ age group in both periods, was 416/100,000 men during 1994-
2001, and 406/100,000 men during 2002-2009.  
 
 
 
Figure 22 
Age-specific mortality rate (ASMR) for colorectal cancer (C18-C20): periods: 1994-2001 and 2002-2009 
 (a) Number of deaths by age group and ASMR (b) percentage (of the total) deaths by age group 
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5.3 International comparison of mortality  
 
An international comparison of estimated 
mortality rates for European countries in 
2008 is presented for colorectal cancer in 
Figure 23.23 
The highest colorectal cancer mortality for 
both men (53/100,000) and women 
(25/100,000) was in Hungary  
Ireland ranked approximately midway of 
the 30 countries shown, with an age 
standardised mortality rate of 28 and 15 per 
100,000 men and women respectively.  
Ireland’s mortality rate was marginally 
higher that of the UK (22 and 14 per 
100,000 men and women respectively) but 
similar to the European average (26 and 
15/100,000 men and women respectively).  
The three countries with the lowest 
recorded mortality rates in 2008 were: 
Cyprus, Greece and Finland.  
  
Figure 23 
Comparisons of age standardised mortality rates (ASMR) for colorectal 
cancer: 2008 
European Cancer Observatory (ECO), 2008.23 
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APPENDIX I 
 
Colorectal cancer: Data sources and dataset 
 
Since 1st January 1994, all newly diagnosed cancers in Ireland have been registered by the National Cancer Registry. The process 
is highly effective. Currently the completeness of cancer registration for all invasive cancers diagnosed to end of 2008 is 
estimated to be over 97%.37 Prior to 1994, there was no national cancer registration and therefore no reliable information on 
cancer incidence.  
The dataset used in this report consisted of all primary invasive colorectal cancers; C18 (colon), C19 (rectosigmoid junction) and 
C20 (rectum), registered by the National Cancer Registry (NCR) with a date of diagnosis from 1 January 1994 to 31 December 
2010. Dataset inclusions and exclusions are shown in Table 47. 
For analysis of incidence and treatment patterns, the dataset was divided into three diagnostic periods: 1995-1999, 2000-2004 
and 2005-2009. For survival analysis, the dataset was divided into three separate diagnostic periods: 1994-1998, 1999-2003 
and 2004-2008. Survival time was censored at 31 December 2009 to ensure that all cases had follow-up for at least one year. 
Only the first primary invasive tumour(s) of the colon and rectum (C18-C20) were included in the survival dataset.  
Colorectal cancers were excluded from survival analyses if they were preceded by another cancer (other than non-melanoma 
skin cancer). Following convention, cases where the sole evidence of cancer was diagnosis from a death certificate or at 
autopsy were excluded from survival analysis. 
  
Table 47 
Cases of colorectal cancer (C18-C20) diagnosed between 1994-2010  in females and males 
 Females Males Total 
Incident cases of malignant colorectal cancer, C18-C20, (1994-2010) 14,381 19,191 33,572 
Exclusions before  survival analysis:        
1. Cases incident during 2009 and 2010 1,930 2,719 4,649 
2. Autopsy and DCO cases (1994-2008) 315 200 515 
3. Cases with another prior or concurrent invasive malignancy (1994-2008)^ 537 954 1,491 
Survival data subset ‡ 11,599 15,318 26,917 
‡ diagnosed during 1994-2008 and all followed up until death or 31/12/09, whichever occurred first 
^ except for non melanoma skin cancer (NMSC) 
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APPENDIX II 
Variable definitions and methods of analysis 
Demographic variables 
Age 
This was the age at diagnosis; the difference between date of birth and date of diagnosis. This variable was available for all 
patients. The EUROCARE convention for age categories in colorectal cancer was used: 15-44 years, 45-54 years, 55-64 years, 65-
74 years and 75+ years. 27 
Smoking status 
Colorectal cancer cases were classified as ‘non smokers’ if they had never smoked, ‘ex-smokers’ if they had ever smoked but 
had not smoked for a year prior to diagnosis. Current smokers were classified as ‘smokers’.  
Marital status  
Colorectal cancer cases were classified as ‘ever married’ if they were married, widowed, divorced or separated, or, ‘never 
married’.  
Date of incidence 
The NCR subscribes to the European Network of Cancer Registries (ENCR) guidance for this data item.28 Date of incidence was 
taken to be the date of histological confirmation (or date of clinical diagnosis if there was no histological confirmation).  
Date of death 
For survival calculations, the last day of follow-up was taken to be 31 December 2009 (censoring date). The date of death was 
taken to be that recorded on the death certificate if available, otherwise the date of death was that observed in the hospital 
case notes.  
HSE area of residence 
All patients in the dataset were allocated to a HSE administrative area according to their main address at the time of diagnosis: 
Dublin Mid Leinster (DNML), Dublin North East (DNNE), West (W) and South (S).  
Deprivation 
Quintiles of deprivation were derived from data in the 2002 census at electoral division (ED) level, and applied to individual 
patients by linkage of address.35 The score consisted of 1 (least deprived) through to 5 (most deprived). 
Tumour characteristics 
TNM 
TNM category of tumour was described in the medical record. Where a pathological T (primary tumour), N (regional nodes) or 
M (distant metastasis) category was given, this was used; otherwise the clinical diagnosis was used. Cases diagnosed between 
1994 and 1999 were staged using version 4 of the TNM AJCC manual.29  Version 5 of the manual was used for cases after 2000. 
Cases where the metastasis was coded as ‘MX’ (unknown) were re-coded to ‘M0’ (i.e. assumed that metastasis had not 
occurred).  
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Summary stage 
Summary stage was derived by algorithm from TNM categories. 
(Table 48) 
Grade 
Tumour grade was transcribed from pathology reports and listed as 1 
(well differentiated), 2 (moderately differentiated), 3 (poorly 
differentiated or undifferentiated) and 4 (unknown). 
Site of primary tumour 
Site of tumour was classified according to ICD10. Two broad sub-categories of colorectal cancer were used throughout the 
report: 
1) Primary tumour in the colon (C18): ‘colon’ 
2) Primary tumour in the rectosigmoid junction (C19) or rectum (C20): ‘rectum’ 
 
Morphology 
Four categories of tumour histology were derived as follows: ‘adenocarcinoma’, ‘mucinous morphology’ and ‘other specified 
morphology’. Morphologies other than these three types were pooled as a single category, ‘other unspecified’.  
Basis of diagnosis 
Cases were classified as microscopically verified if the tumour had been confirmed by histological or cytological methods. Cases 
were classified as clinically verified if diagnosed by radiology, ultrasound or by autopsy. 
Treatment definitions 
The focus was on tumour-directed treatment administered within one year of the diagnosis date. This was interpreted as the 
primary course of treatment aimed at removing, reducing, destroying or preventing further growth of tumour. No distinction 
was made between ‘curative’ and ‘palliative’ treatment. For the purposes of this report, five treatment scenarios (a-e) were 
defined as follows: 
a) Surgery  
A case was considered to have undergone surgery if at least one tumour resection was recorded (ICD-9-CM procedure 
codes 45.4x, 45.7x, 45.8, 48.3, 48.35, 48.36, 48.4, 48.49, 48.5, 48.6x, 48.82).41 
b) chemotherapy 
A case was considered to have undergone chemotherapy if at least one chemotherapeutic agent was administered. 
Chemotherapy administered before surgery was referred to as neo-adjuvant chemotherapy, and after surgery, as adjuvant 
chemotherapy. 
c) Radiotherapy 
A case was considered to have undergone radiotherapy if least one radiotherapy session was recorded. Pre-operative and 
post-operative radiotherapy was recorded.  
d) Treated 
A case was considered to have been treated if at least one treatment was recorded for that case (i.e. treatment as defined 
in a-c above). 
Table 48 
Stage grouping: colorectal cancer 
 T  
size 
N  
nodes 
M 
‘mets’ 
Dukes
Stage 0 Tis N0 M0 - 
Stage I T1 N0 M0 A 
 T2 N0 M0 A 
Stage II T3 N0 M0 B 
 T4 N0 M0 B 
Stage III Any T N1 M0 C 
 Any T N2 M0 C 
 Any T N3 M0 C 
Stage IV Any T Any N M1 - 
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e) Not treated 
A case was considered as not treated if there was no treatment recorded for that case as defined in a-d above. However, 
many cases had other types of medical and surgical interventions not covered in a-c above. 
Statistical methods 
Age standardised rates (ASR) for incidence and mortality were weighted by the European standard population. Annual 
percentage change (APC) of incidence and mortality over time was calculated using the Joinpoint regression program.30   
Joinpoint regression was also used to test for linear trend over time for selected variables in sections 2 (incidence) and 3 
(treatment).  
Standardised rate ratios (SRR) were calculated for the period 2004-2008. The age standardised (ASR) incidence rate is the 
proportion of cases in a given population (and year) weighted by the European age structure. Rather than consider the most 
recent year (2008), the numbers of cases occurring during 2004-2008 in Ireland were summed and divided by the sum of 
persons at risk in Ireland (summed for 2004-2008) using intercensal population estimates. The ASR for 2004-2008 was 
calculated for each county in a similar fashion. The ratio of county ASR over country ASR gives the standardised rate ratio (SRR). 
The 95% CI of the SRR ratio was also calculated.31 A county was considered to have a significantly higher (or lower) incidence of 
cases than the national average if the 95% confidence interval of the SRR did not include unity.  
Variables affecting treatment receipt were identified using logistic regression. An explanatory variable was included in a final 
model if the likelihood ratio test for exclusion of that variable from the multivariate model had a p-value less than 0.10. As 
treatment was common, the odds ratio overestimated the risk of treatment when it was more than 1 or underestimated the 
risk when it was less than 1. To overcome this problem, odds ratios were converted to risk ratios (RR) according to the formula 
RR=[OR]/[(1-P0)+(ORxP0)] where OR is the odds ratio for a group of patients who received treatment relative to the baseline 
group, and the proportion of patients treated in the baseline group is give by P0.
32 Looking at tables of adjusted RR’s leads to 
the same conclusions as adjusted OR’s; except that the RR can be conveniently interpreted as the proportion who received 
treatment relative to the baseline level of a variable.  
Survival data is presented as relative survival (RS); the ratio of observed survival among a group of cases to the expected 
survival among the general population of the same age, sex and country. Relative survival was calculated using the ‘strs’ 
command in STATA 11.0.33 RS was derived for each level of the variables: i.e., diagnostic period, stage etc. As the life tables (for 
RoI) used to calculate relative survival did not take account of deprivation quintiles, cause specific survival for each quintile of 
the deprivation score was calculated using the Kaplan-Meier method. The effect of diagnostic period on cause specific survival 
was determined using Cox proportional hazards regression models, stratified by age, sex, stage and site of primary tumour. An 
explanatory variable was included in the final Cox model if the likelihood ratio test for exclusion of that variable from the 
multivariate model had a p-value less than 0.10.  
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APPENDIX III 
Treatment administration 
Table 49  Temporal sequence of treatment administration, by site of tumour, stage and period of diagnosis 
Site of primary tumour: colon (C18) Site of primary tumour: rectum (C19-20) 
Treatments in temporal 1995-1999 2000-2004 2005-2009 
sequence of administration  n %  n %  n % 
Stage I 
a_surgery 635 89.2 625 90.1 728 90.9 
b_surgery_chemotherapy 45 6.3 39 5.6 26 3.2 
c_surgery_chemotherapy_radiation 9 1.3 2 0.3 0 - 
e_chemotherapy_radiation_surgery 0 - 0 - 1 0.1 
f_chemotherapy_surgery 0 - 1 0.1 1 0.1 
g_surgery_radiation 4 0.6 1 0.1 3 0.4 
h_radiation_surgery 1 0.1 0 - 1 0.1 
j_chemotherapy 0 - 3 0.4 1 0.1 
k_radiation 0 - 0 - 1 0.1 
l_chemotherapy_radiation 0 - 2 0.3 1 0.1 
m_no_treatment 18 2.5 21 3.0 38 4.7 
Total 712 100 694 100 801 100 
Stage II 
a_surgery 1,203 66.5 1,196 65.9 1,471 69 
b_surgery_chemotherapy 391 21.6 435 24 477 22.4 
c_surgery_chemotherapy_radiation 49 2.7 39 2.1 36 1.7 
e_chemotherapy_radiation_surgery 0 - 2 0.1 7 0.3 
f_chemotherapy_surgery 4 0.2 4 0.2 4 0.2 
g_surgery_radiation 25 1.4 13 0.7 14 0.7 
h_radiation_surgery 0 - 4 0.2 2 0.1 
i_radiation_surgery_chemotherapy 1 0.1 0 - 0 - 
j_chemotherapy 14 0.8 12 0.7 17 0.8 
k_radiation 6 0.3 4 0.2 2 0.1 
l_chemotherapy_radiation 2 0.1 3 0.2 3 0.1 
m_no_treatment 115 6.4 102 5.6 99 4.6 
Total 1,810 100 1,814 100 2,132 100 
Stage III 
a_surgery 594 49.5 541 37.1 636 33.3 
b_surgery_chemotherapy 479 39.9 780 53.4 1,099 57.5 
c_surgery_chemotherapy_radiation 55 4.6 53 3.6 55 2.9 
d_chemotherapy_surgery_radiation 0 - 0 - 1 0.1 
e_chemotherapy_radiation_surgery 1 0.1 1 0.1 12 0.6 
f_chemotherapy_surgery 4 0.3 2 0.1 10 0.5 
g_surgery_radiation 28 2.3 19 1.3 6 0.3 
h_radiation_surgery 0 - 0 - 2 0.1 
i_radiation_surgery_chemotherapy 0 - 0 - 1 0.1 
j_chemotherapy 10 0.8 18 1.2 19 1.0 
k_radiation 1 0.1 1 0.1 3 0.2 
l_chemotherapy_radiation 3 0.3 1 0.1 0 - 
m_no_treatment 24 2.0 44 3.0 66 3.5 
Total 1,199 100 1,460 100 1,910 100 
Stage IV 
a_surgery 352 29.3 302 20.9 280 16.7 
b_surgery_chemotherapy 250 20.8 364 25.2 523 31.2 
c_surgery_chemotherapy_radiation 17 1.4 28 1.9 21 1.3 
d_chemotherapy_surgery_radiation 1 0.1 1 0.1 3 0.2 
e_chemotherapy_radiation_surgery 0 - 2 0.1 2 0.1 
f_chemotherapy_surgery 7 0.6 20 1.4 27 1.6 
g_surgery_radiation 9 0.7 6 0.4 5 0.3 
h_radiation_surgery 1 0.1 0 - 1 0.1 
i_radiation_surgery_chemotherapy 0 - 0 - 1 0.1 
j_chemotherapy 96 8 210 14.5 322 19.2 
k_radiation 7 0.6 20 1.4 20 1.2 
l_chemotherapy_radiation 5 0.4 16 1.1 25 1.5 
m_no_treatment 457 38 476 32.9 448 26.7 
Total 1,202 100 1,445 100 1,678 100 
Unstaged 
a_surgery 124 17.6 131 19.7 190 27.9 
b_surgery_chemotherapy 7 1.0 17 2.6 21 3.1 
c_surgery_chemotherapy_radiation 1 0.1 0 - 2 0.3 
e_chemotherapy_radiation_surgery 1 0.1 1 0.2 5 0.7 
f_chemotherapy_surgery 0 - 1 0.2 8 1.2 
g_surgery_radiation 3 0.4 0 - 1 0.1 
h_radiation_surgery 0 - 1 0.2 2 0.3 
i_radiation_surgery_chemotherapy 0 - 0 - 2 0.3 
j_chemotherapy 5 0.7 11 1.7 24 3.5 
k_radiation 4 0.6 7 1.1 3 0.4 
l_chemotherapy_radiation 0 - 3 0.5 1 0.1 
m_no_treatment 559 79.4 493 74.1 421 61.9 
Total 704 100 665 100 680 100 
 
Treatments in temporal 1995-1999 2000-2004 2005-2009 
sequence of administration  n %  n %  n % 
Stage I 
a_surgery 544 83.6 491 74.1 432 73.1 
b_surgery_chemotherapy 20 3.1 17 2.6 9 1.5 
c_surgery_chemotherapy_radiation 18 2.8 34 5.1 14 2.4 
e_chemotherapy_radiation_surgery 4 0.6 35 5.3 66 11.2 
f_chemotherapy_surgery 0 - 2 0.3 0 - 
g_surgery_radiation 15 2.3 14 2.1 11 1.9 
h_radiation_surgery 4 0.6 18 2.7 20 3.4 
i_radiation_surgery_chemotherapy 1 0.2 3 0.5 0 - 
j_chemotherapy 0 - 2 0.3 2 0.3 
k_radiation 6 0.9 10 1.5 5 0.8 
l_chemotherapy_radiation 5 0.8 11 1.7 3 0.5 
m_no_treatment 34 5.2 26 3.9 29 4.9 
Total 651 100 663 100 591 100 
Stage II 
a_surgery 434 52.5 309 37.2 310 37.7 
b_surgery_chemotherapy 73 8.8 86 10.4 81 9.9 
c_surgery_chemotherapy_radiation 117 14.2 119 14.3 57 6.9 
d_chemotherapy_surgery_radiation 0 - 1 0.1 0 - 
e_chemotherapy_radiation_surgery 22 2.7 103 12.4 191 23.2 
f_chemotherapy_surgery 3 0.4 6 0.7 3 0.4 
g_surgery_radiation 46 5.6 37 4.5 18 2.2 
h_radiation_surgery 18 2.2 25 3.0 41 5.0 
i_radiation_surgery_chemotherapy 5 0.6 13 1.6 16 1.9 
j_chemotherapy 4 0.5 5 0.6 3 0.4 
k_radiation 19 2.3 30 3.6 31 3.8 
l_chemotherapy_radiation 18 2.2 34 4.1 25 3.0 
m_no_treatment 67 8.1 62 7.5 46 5.6 
Total 826 100 830 100 822 100 
Stage III 
a_surgery 250 37.9 191 20.2 195 16.8 
b_surgery_chemotherapy 144 21.9 188 19.9 255 21.9 
c_surgery_chemotherapy_radiation 173 26.3 248 26.2 138 11.9 
d_chemotherapy_surgery_radiation 2 0.3 2 0.2 0 - 
e_chemotherapy_radiation_surgery 7 1.1 136 14.4 334 28.7 
f_chemotherapy_surgery 2 0.3 11 1.2 14 1.2 
g_surgery_radiation 46 7.0 36 3.8 21 1.8 
h_radiation_surgery 9 1.4 22 2.3 45 3.9 
i_radiation_surgery_chemotherapy 2 0.3 28 3.0 38 3.3 
j_chemotherapy 2 0.3 7 0.7 12 1 
k_radiation 5 0.8 24 2.5 23 2 
l_chemotherapy_radiation 6 0.9 26 2.8 49 4.2 
m_no_treatment 11 1.7 26 2.8 40 3.4 
Total 659 100 945 100 1,164 100 
Stage IV 
a_surgery 158 24.6 78 10.9 67 8.7 
b_surgery_chemotherapy 92 14.3 137 19.2 155 20.1 
c_surgery_chemotherapy_radiation 40 6.2 35 4.9 18 2.3 
d_chemotherapy_surgery_radiation 0 - 3 0.4 2 0.3 
e_chemotherapy_radiation_surgery 5 0.8 25 3.5 42 5.4 
f_chemotherapy_surgery 3 0.5 3 0.4 17 2.2 
g_surgery_radiation 20 3.1 12 1.7 10 1.3 
h_radiation_surgery 4 0.6 8 1.1 5 0.6 
i_radiation_surgery_chemotherapy 2 0.3 5 0.7 13 1.7 
j_chemotherapy 38 5.9 98 13.7 154 19.9 
k_radiation 34 5.3 41 5.8 50 6.5 
l_chemotherapy_radiation 41 6.4 75 10.5 70 9.1 
m_no_treatment 206 32.0 193 27.1 170 22.0 
Total 643 100 713 100 773 100 
Unstaged 
a_surgery 86 20.3 78 18.4 84 17.2 
b_surgery_chemotherapy 0 - 5 1.2 7 1.4 
c_surgery_chemotherapy_radiation 4 0.9 4 0.9 8 1.6 
d_chemotherapy_surgery_radiation 0 - 1 0.2 0 - 
e_chemotherapy_radiation_surgery 14 3.3 37 8.7 78 16 
f_chemotherapy_surgery 0 - 3 0.7 17 3.5 
g_surgery_radiation 8 1.9 2 0.5 10 2.1 
h_radiation_surgery 9 2.1 9 2.1 19 3.9 
i_radiation_surgery_chemotherapy 7 1.7 5 1.2 7 1.4 
j_chemotherapy 5 1.2 15 3.5 20 4.1 
k_radiation 24 5.7 30 7.1 20 4.1 
l_chemotherapy_radiation 14 3.3 14 3.3 23 4.7 
m_no_treatment 253 59.7 222 52.2 194 39.8 
Total 424 100 425 100 487 100 
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